<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clindamycin (systemic): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clindamycin (systemic): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Clindamycin (systemic): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11601" href="/d/html/11601.html" rel="external">see "Clindamycin (systemic): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="15953" href="/d/html/15953.html" rel="external">see "Clindamycin (systemic): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F8007987"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Colitis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<i>Clostridioides</i>
<i>difficile</i>-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including clindamycin, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of <i>C. difficile</i>.</p>
<p style="text-indent:-4em;margin-left:4em;">Because clindamycin therapy has been associated with severe colitis, which may end fatally, reserve it for serious infections for which less toxic antimicrobial agents are inappropriate. Do not use clindamycin in patients with nonbacterial infections, such as most upper respiratory tract infections.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>C. difficile</i> produces toxins A and B, which contribute to the development of CDAD. Hypertoxin-producing strains of <i>C. difficile</i> cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary because CDAD has been reported to occur more than 2 months after the administration of antibacterial agents.</p>
<p style="text-indent:-2em;margin-left:2em;">If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <i>C. difficile</i> may need to be discontinued. Institute appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <i>C. difficile</i>, and surgical evaluation as clinically indicated.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F8008032"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Cleocin;</li>
<li>Cleocin Phosphate</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52869085"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>AG-Clindamycin;</li>
<li>APO-Clindamycin [DSC];</li>
<li>Auro-Clindamycin;</li>
<li>Clindamycine-150 [DSC];</li>
<li>Clindamycine-300 [DSC];</li>
<li>Dalacin C;</li>
<li>Dalacin C Palmitate;</li>
<li>Dalacin C Phosphate;</li>
<li>JAMP Clindamycin;</li>
<li>M-Clindamycin;</li>
<li>MED-Clindamycin;</li>
<li>NRA-Clindamycin;</li>
<li>RIVA-Clindamycin;</li>
<li>TEVA-Clindamycin</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F8008037"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antibiotic, Lincosamide</li></ul></div>
<div class="block doa drugH1Div" id="F8008117"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Usual dose:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 600 mg to 1.8 g/day in 2 to 4 divided doses.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM, IV:</b> 600 mg to 2.7 g/day in 2 to 4 divided doses; according to the manufacturer, up to 4.8 g/day IV (in divided doses) has been used in life-threatening infections; however, data supporting this dose are lacking; maximum: 600 mg/dose IM.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c74e9b7c-3d24-4a43-8fa5-6da3c93d72db">Anthrax</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anthrax (off-label use): Note:</b> Consult public health officials for event-specific recommendations.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Inhalational (postexposure prophylaxis) (alternative agent):</i>
<b>Oral:</b> 600 mg every 8 hours for 42 to 60 days; duration depends on anthrax vaccine status and series completion, age, immune status, and pregnancy/breastfeeding status. For those who have not previously received an anthrax vaccine, duration ranges from 42 to 60 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31834290']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31834290'])">Ref</a></span>). Some experts favor longer durations of prophylaxis (eg, total of 3 to 4 months) for patients who are immunocompromised or remain unvaccinated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wilson.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wilson.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Anthrax vaccine should also be administered to exposed individuals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31834290','lexi-content-ref-24447897']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31834290','lexi-content-ref-24447897'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cutaneous, without systemic involvement, empiric therapy (alternative agent):</i>
<b>Oral:</b> 600 mg every 8 hours for 60 days following biological weapon-related event; duration is 7 to 10 days after naturally acquired infection. <b>Note:</b> Treat patients with extensive edema or cutaneous lesions of the head or neck with a parenteral regimen recommended for systemic involvement (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24447897']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24447897'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Systemic (with or without meningitis):</i>
<b>IV:</b> 900 mg every 8 hours in combination with other appropriate agents for ≥2 to 3 weeks or until clinically stable, whichever is longer (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24447897']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24447897'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Antitoxin should also be administered for systemic anthrax. Following the course of IV combination therapy for systemic anthrax infection (including meningitis), patients exposed to aerosolized spores require oral monotherapy to complete a total antimicrobial course of 60 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24447897']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24447897'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2c04f789-5b51-49cc-b68d-d3d58ad6925e">Babesiosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Babesiosis (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mild to moderate disease or oral step-down therapy following initial parenteral treatment:</i>
<b>Oral:</b> 600 mg every 8 hours in combination with quinine for a total of 7 to 10 days; a longer duration of ≥6 weeks, including 2 weeks after resolution of parasitemia, may be necessary for patients at high risk of relapse (eg, highly immunocompromised patients) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33501959','lexi-content-ref-18181735','lexi-content-ref-27115378']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33501959','lexi-content-ref-18181735','lexi-content-ref-27115378'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Severe disease, initial therapy:</i>
<b>IV:</b> 600 mg every 6 hours in combination with quinine; may switch to oral clindamycin once symptoms improve (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33501959']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33501959'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f74ecf56-4df6-48d7-b60e-9165458d8fec">Bacterial vaginosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bacterial vaginosis (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Treatment is generally not warranted for patients who are asymptomatic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 300 mg twice daily for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bf0996fd-b1e3-4d3a-a9a0-7f24593cec52">Bite wound infection, prophylaxis of high-risk bite or treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bite wound infection, prophylaxis of high-risk bite or treatment (animal or human bite) (alternative agent) (off-label use): Note:</b> For animal bite, use in combination with an appropriate agent for <i>Pasteurella multocida</i>. For human bite, use in combination with an appropriate agent for <i>Eikenella corrodens</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 300 to 450 mg 3 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Baddour.2','lexi-content-ref-Baddour.1','lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Baddour.2','lexi-content-ref-Baddour.1','lexi-content-ref-24947530'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 600 mg every 6 to 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530'])">Ref</a></span>). <b>Note:</b> In selected patients with high-risk wounds, some experts recommend parenteral therapy be given initially until infection is resolving, followed by oral therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Baddour.2','lexi-content-ref-Baddour.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Baddour.2','lexi-content-ref-Baddour.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For prophylaxis, duration is 3 to 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530'])">Ref</a></span>); for treatment of established infection, duration is typically 5 to 14 days and varies based on patient-specific factors, including clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Baddour.2','lexi-content-ref-Baddour.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Baddour.2','lexi-content-ref-Baddour.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2e598d8e-f681-420c-9f01-28a8efdcdac6">Diabetic foot infection, mild to moderate</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetic foot infection, mild to moderate (alternative agent) (off-label use):</b>
<b>Oral:</b> 300 to 450 mg every 6 to 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18649613','lexi-content-ref-22619242','lexi-content-ref-2183732','lexi-content-ref-Weintrob.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18649613','lexi-content-ref-22619242','lexi-content-ref-2183732','lexi-content-ref-Weintrob.2018'])">Ref</a></span>). <b>Note:</b> May be used alone for empiric therapy of mild infections; if there are risk factors for gram-negative bacilli, must be used in combination with other appropriate agents. Duration of therapy should be tailored to individual clinical circumstances; most patients respond to 1 to 2 weeks of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22619242','lexi-content-ref-Weintrob.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22619242','lexi-content-ref-Weintrob.2018'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="13fffee0-1f22-4047-ad66-3a4e6e6716e0">Gingivitis, acute simple, plaque-associated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gingivitis, acute simple, plaque-associated (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For patients unable to take beta-lactams. Reserve systemic therapy for patients with rapidly progressive disease, severe pain, or immunocompromising conditions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Chow.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Chow.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 450 mg every 8 hours for 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Chow.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Chow.2018'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a1a5c771-d06c-4f42-a40c-2a0c6db81cba">Hidradenitis suppurativa</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hidradenitis suppurativa (off-label use): Oral:</b> 300 mg twice daily in combination with rifampin for 10 to 12 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30872149','lexi-content-ref-27753139','lexi-content-ref-19590173','lexi-content-ref-26831295','lexi-content-ref-25640693']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30872149','lexi-content-ref-27753139','lexi-content-ref-19590173','lexi-content-ref-26831295','lexi-content-ref-25640693'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="907db476-c453-431b-8e3f-050c1461baaf">Malaria, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Malaria, treatment (alternative agent) (off-label use): Oral:</b> 20 mg/kg/<b>day</b> in divided doses every 8 hours for 7 days, as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.3'])">Ref</a></span>); oral doses generally do not exceed 1.8 <b>g</b>/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>). <b>Note:</b> If used for severe malaria (after completion of IV therapy), use full 7-day schedule of clindamycin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.3'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1378dcb0-a2fc-424f-8753-558943d5f1e0">Mastitis, lactational</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mastitis, lactational (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Reserve for patients unable to use first-line agents or for patients at risk for methicillin-resistant <i>S. aureus</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35576513']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35576513'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>300 mg 4 times daily <b>or</b> 450 mg 3 times daily for 10 to 14 days; shorter courses (eg, 5 to 7 days) may be considered for patients with rapid clinical resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35576513','lexi-content-ref-Dixon.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35576513','lexi-content-ref-Dixon.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ebce2e15-5575-4944-a590-3bb61b8252c0">Neutropenic fever, empiric therapy for low-risk patients with cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neutropenic fever, empiric therapy for low-risk </b>
<b>patients with </b>
<b>cancer (alternative agent for penicillin-allergic patients) (off-label use):</b>
<b>Oral:</b> 600 mg every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8490912']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8490912'])">Ref</a></span>); some experts recommend 300 mg every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bow.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bow.2018'])">Ref</a></span>) (data on appropriate dose are limited). Use in combination with oral ciprofloxacin; continue until afebrile and neutropenia has resolved. <b>Note:</b> Avoid in patients who have received fluoroquinolone prophylaxis. Administer first dose in the health care setting (after blood cultures are drawn); observe patient for ≥4 hours before discharge (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29461916','lexi-content-ref-21258094']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29461916','lexi-content-ref-21258094'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a9d9ff41-d96a-4eb8-b9f5-e76594705fc3">Osteomyelitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteomyelitis</b>
<b>:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Osteomyelitis due to methicillin-resistant Staphylococcus aureus (MRSA) (alternative agent)</i>: <b>IV, Oral:</b> 600 mg 3 times daily for a minimum of 8 weeks; some experts combine with rifampin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21217178']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21217178'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Osteomyelitis, native vertebral due to staphylococci, methicillin-susceptible (alternative agent)</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 600 to 900 mg every 8 hours for 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26229122']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26229122'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral<i>: </i></b>300 to 450 mg 4 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26229122']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26229122'])">Ref</a></span>) or 600 mg 3 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21217178']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21217178'])">Ref</a></span>) for 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26229122']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26229122'])">Ref</a></span>). <b>Note:</b> Clindamycin may also be used as suppressive therapy in selected patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Osmon.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Osmon.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Osteomyelitis, native vertebral due to Cutibacterium acnes </i>
<i>(alternative agent):</i>
<b>IV:</b> 600 to 900 mg every 8 hours for 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26229122']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26229122'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="673935b0-488d-4ad3-b68d-461dbf301024">Pelvic inflammatory disease, severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pelvic inflammatory disease, severe (including tubo-ovarian abscess) (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 900 mg every 8 hours in combination with gentamicin; after 24 to 48 hours of sustained clinical improvement, transition to an oral regimen to complete 14 days of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).<b> Note:</b> Some experts reserve this regimen for patients who cannot use preferred agents due to greater associated adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wiesenfeld.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wiesenfeld.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b> Oral:</b> 450 mg 4 times daily, beginning after 24 to 48 hours of sustained clinical improvement on an appropriate parenteral regimen, to complete 14 days of therapy. <b>Note: </b>If tubo-ovarian abscess is present, use as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c8f01ae1-8bb4-46b0-a53d-24f5962b66de">
<i>Pneumocystis jirovecii</i> pneumonia, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Pneumocystis</i></b>
<b>
<i>jirovecii </i></b>
<b>pneumonia (PCP), treatment (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate disease: <b>Oral:</b> 450 mg every 6 hours or 600 mg every 8 hours with primaquine for 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Severe disease: <b>IV:</b> 600 mg every 6 hours or 900 mg every 8 hours with primaquine for 21 days; following clinical improvement, clindamycin can be given orally at 450 mg every 6 hours or 600 mg every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2','lexi-content-ref-Thomas.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2','lexi-content-ref-Thomas.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Patients with moderate or severe infection (PaO<sub>2</sub> &lt;70 mm Hg at room air or alveolar-arterial oxygen gradient ≥35 mm Hg) should receive adjunctive glucocorticoids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7792e77c-7758-4230-a81e-dc7dd3a6acb9">Pneumonia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Aspiration pneumonia (alternative agent):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Reserve for patients with penicillin allergy, as initial treatment for mild, community-acquired infection or as oral step-down therapy for patients requiring initial parenteral therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Klompas.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Klompas.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 300 to 450 mg 3 times daily; duration of therapy is generally 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14759242','lexi-content-ref-Klompas.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14759242','lexi-content-ref-Klompas.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pathogen-specific therapy for methicillin-resistant </i>
<i>S. aureus</i>
<i> pneumonia (alternative agent):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Data in adults are limited (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21217178','lexi-content-ref-20173050']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21217178','lexi-content-ref-20173050'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral, IV:</b> 600 mg 3 times daily; duration of therapy varies based on disease severity and response to therapy; treatment is typically given for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21217178']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21217178'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="03fe69ef-7449-492c-b41a-4f0f2868f0da">Postpartum endometritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Postpartum endometritis: IV:</b> 900 mg every 8 hours as part of an appropriate combination regimen; treat until the patient is clinically improved (no fundal tenderness) and afebrile for 24 to 48 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Chen.2018','lexi-content-ref-8866384']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Chen.2018','lexi-content-ref-8866384'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9d1b4c51-5035-4766-b50d-dd4e58990353">Prosthetic joint infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prosthetic joint infection (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cutibacterium acnes, treatment (alternative agent for penicillin allergy):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 600 to 900 mg every 8 hours for 4 to 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23223583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23223583'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 300 to 450 mg every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23223583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23223583'])">Ref</a></span>), following at least 2 weeks of parenteral therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kanafani.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kanafani.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Methicillin-resistant staphylococci, treatment (chronic suppression):</i>
<b>Oral:</b> 600 mg every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Berbari.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Berbari.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1437b55a-5145-4c15-bba4-c28709c37109">Rhinosinusitis, acute bacterial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rhinosinusitis, acute bacterial (alternative agent for patients with penicillin allergy who are able to tolerate cephalosporins) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> In uncomplicated acute bacterial rhinosinusitis, initial observation and symptom management without antibiotic therapy is appropriate in most patients. Reserve antibiotic therapy for poor follow-up or lack of improvement over the observation period (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25832968','lexi-content-ref-26785402']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25832968','lexi-content-ref-26785402'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>300 mg every 6 to 8 hours in combination with an oral third-generation cephalosporin for 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27602668','lexi-content-ref-22438350','lexi-content-ref-Patel.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27602668','lexi-content-ref-22438350','lexi-content-ref-Patel.2018'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ff36a9c1-bb12-4008-a586-8b5bb8d70553">Septic arthritis due to <i>S. aureus</i></span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Septic arthritis due to </b>
<i>
<b>S. aureus</b></i>
<b> (including MRSA) (alternative agent):</b>
<b>Oral, IV:</b> 600 mg 3 times daily for 3 to 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goldenberg.2019','lexi-content-ref-21217178']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goldenberg.2019','lexi-content-ref-21217178'])">Ref</a></span>). <b>Note</b>: A longer course of parenteral therapy (4 weeks) may be required for patients with concomitant bacteremia (in the absence of endocarditis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goldenberg.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goldenberg.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5fe294fd-4626-4e48-9579-84675accedc8">Skin and soft tissue infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Abscess: </i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Systemic antibiotics may be reasonably withheld in healthy, immunocompetent patients with a single, small abscess that has been drained if they are clinically well and have no indwelling device, risk factors for endocarditis, or risk for MRSA transmission (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530','lexi-content-ref-Spelman.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530','lexi-content-ref-Spelman.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral: </b>300 mg 4 times daily or 450 mg 3 times daily for ≥5 days; may extend up to 14 days depending on severity and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530','lexi-content-ref-Spelman.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530','lexi-content-ref-Spelman.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cellulitis, purulent or with risk for methicillin-resistant S. aureus or erysipelas:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral: </b>300 mg 4 times daily or 450 mg 3 times daily for ≥5 days; may extend up to 14 days depending on severity and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530','lexi-content-ref-Spelman.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530','lexi-content-ref-Spelman.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV: </b>600 to 900 mg every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Duration: Treat for ≥5 days but may extend up to 14 days depending on severity and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530','lexi-content-ref-Spelman.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530','lexi-content-ref-Spelman.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cellulitis, long-term suppression of recurrent infection:</i>
<b>Note:</b> For patients with recurrent presumptive staphylococcal cellulitis at the same anatomical site despite addressing predisposing factors; reserve for patients who cannot use other options (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Spelman.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Spelman.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral: </b>150 mg once daily after completion of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3184334','lexi-content-ref-Spelman.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3184334','lexi-content-ref-Spelman.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Impetigo or ecthyma if methicillin-resistant S. aureus is suspected or confirmed:</i>
<b>Note:</b> For impetigo, reserve systemic therapy for patients with numerous lesions or in outbreak settings to decrease transmission (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 300 mg 4 times daily or 450 mg 3 times daily for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Baddour.3','lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Baddour.3','lexi-content-ref-24947530'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Necrotizing soft tissue infection:</i>
<b> IV:</b> 600 to 900 mg every 8 hours as part of an appropriate combination regimen. <b>Note:</b> Antibiotic therapy must be used in conjunction with early and aggressive surgical exploration and debridement of necrotic tissue (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530','lexi-content-ref-Stevens.2018a']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530','lexi-content-ref-Stevens.2018a'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d3f2098d-7a15-436e-bc6b-422791b57466">
<i>Streptococcus</i>, group A</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Streptococcus</i>, group A:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Bloodstream infection:</i>
<b>IV:</b> 900 mg every 8 hours in combination with IV penicillin G; duration is individualized, but clindamycin may be discontinued within 48 hours for patients without septic shock, organ failure, or necrotizing infection. Continue an appropriate antistreptococcal agent to complete ≥14 days of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stevens.2019b']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stevens.2019b'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pharyngitis (alternative agent for penicillin-allergic patients) (off-label use):</i>
<b>Oral:</b> 300 mg 3 times daily for 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22965026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22965026'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chronic carriage (off-label use):</i>
<b>Oral:</b> 300 mg 3 times daily for 10 days. <b>Note:</b> Most individuals with chronic carriage do not require antimicrobial treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22965026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22965026'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f5dece5b-2d11-47e5-889d-c077e5335caf">
<i>Streptococcus</i>, group B, maternal prophylaxis for prevention of neonatal disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Streptococcus</i>, group B</b>
<b>, maternal prophylaxis for prevention of neonatal disease (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 900 mg at onset of labor or prelabor rupture of membranes, then every 8 hours until delivery.<b> Note:</b> Reserve use for patients with penicillin allergy that are at high risk for anaphylaxis and who have documented clindamycin-susceptible group B streptococci (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31977795']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31977795'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fa7b6aef-11c5-4b72-97a0-a39f0f808184">Surgical prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical prophylaxis (in combination with other appropriate agents when coverage for MRSA is indicated or for gram-positive coverage in patients unable to tolerate cephalosporins) (off-label use): </b>
<b>IV:</b> 900 mg started within 60 minutes prior to initial surgical incision. Clindamycin doses may be repeated intraoperatively at 6-hour intervals if procedure is lengthy or if there is excessive blood loss (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23327981'])">Ref</a></span>). In cases where an extension of prophylaxis is warranted postoperatively, total duration should be ≤24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24799638','lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24799638','lexi-content-ref-23327981'])">Ref</a></span>). For clean and clean-contaminated procedures, continued prophylactic antibiotics beyond surgical incision closure is not recommended, even in the presence of a drain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28467526']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28467526'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cd360816-1f04-4a66-b502-2527e447fdef">Toxic shock syndrome, toxin production suppression</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Toxic shock syndrome, toxin production suppression (empiric therapy):</b>
<b>IV:</b> 900 mg every 8 hours as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19393958','lexi-content-ref-23809722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19393958','lexi-content-ref-23809722'])">Ref</a></span>). Duration is until clinically and hemodynamically stable for ≥48 to 72 hours; then discontinue clindamycin and give monotherapy with an appropriate agent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Chu.2019','lexi-content-ref-Stevens.2019b']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Chu.2019','lexi-content-ref-Stevens.2019b'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a8b5b653-4b09-40a3-8afe-b94617a27205">
<i>Toxoplasma gondii</i> encephalitis and pneumonitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Toxoplasma gondii</b></i>
<b>encephalitis and pneumonitis (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Initial treatment: <b>Oral, IV:</b> 600 mg every 6 hours in combination with pyrimethamine and leucovorin. Continue therapy for at least 6 weeks; longer duration may be required if incomplete response or extensive disease; after completion of acute therapy, all patients should receive long-term maintenance therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23465021','lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23465021','lexi-content-ref-HHS.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Chronic maintenance therapy: <b>Oral:</b> 600 mg every 8 hours in combination with pyrimethamine and leucovorin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23465021','lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23465021','lexi-content-ref-HHS.2'])">Ref</a></span>); in patients with HIV, may discontinue when asymptomatic with a CD4 count &gt;200 cells/mm<sup>3</sup> and an undetectable HIV viral load for &gt;6 months in response to ART (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990716"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV, Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Mild to severe impairment:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Poorly dialyzed; no supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-5780400']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-5780400'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> Poorly dialyzed; no dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1211913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1211913'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19397464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19397464'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988067"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment: There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate to severe impairment: There are no dosage adjustments provided in the manufacturer's labeling. In studies of patients with moderate or severe liver disease, half-life is prolonged; however, when administered on an every-8-hour schedule, accumulation should rarely occur. In severe liver disease, use caution and monitor liver enzymes periodically during therapy.</p></div>
<div class="block doe drugH1Div" id="F8008118"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F8008116"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="15953" href="/d/html/15953.html" rel="external">see "Clindamycin (systemic): Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: </b>Dosing presented in mg/kg/dose and mg/kg/<b>day</b>; use caution. Dosage should be based on total body weight for children ≥2 years of age and adolescents with and without obesity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28137820','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28137820','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing, susceptible infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">IM, IV: 20 to 40 mg/kg/<b>day </b>divided every 6 to 8 hours; maximum daily dose: 2,700 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: 10 to 25 mg/kg/<b>day</b> divided every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1','lexi-content-ref-manu.1'])">Ref</a></span>); higher doses of 30 to 40 mg/kg/<b>day</b> divided every 6 to 8 hours recommended for some infections; maximum daily dose: 1,800 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c74e9b7c-3d24-4a43-8fa5-6da3c93d72db">Anthrax</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anthrax:</b>
<b>Note: </b>Consult public health officials for event-specific recommendations. After completion of therapy, initiate antimicrobial prophylaxis to complete an antimicrobial course of 60 days from onset of illness.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Limited data available:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Postexposure prophylaxis (inhalational exposure)</i>: Oral: 30 mg/kg/<b>day</b> divided every 8 hours for 60 days; maximum dose: 900 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Cutaneous, without systemic involvement</i>: Oral: 30 mg/kg/<b>day</b> divided every 8 hours for 7 to 10 days for a naturally acquired infection or 60 days for a biological weapon-related event; maximum dose: 600 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Systemic involvement (including severe disease)</i>: IV: 40 mg/kg/<b>day</b> divided every 8 hours as part of an appropriate combination regimen for ≥14 days if meningitis is excluded or ≥14 to 21 days if meningitis cannot be excluded, and until patient clinically stable; maximum dose: 900 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Step-down therapy for severe infection</i>: Oral: 30 mg/kg/<b>day</b> divided every 8 hours as part of an appropriate combination regimen to complete ≥14 days total therapy following appropriate initial treatment; maximum dose: 600 mg/dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2c04f789-5b51-49cc-b68d-d3d58ad6925e">Babesiosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Babesiosis (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Limited data available:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Mild to moderate disease or oral step-down therapy following initial parenteral treatment:</i> Oral: 7 to 10 mg/kg/dose every 6 to 8 hours in combination with quinine for a total of 7 to 10 days; maximum dose: 600 mg/dose. A longer duration of ≥6 weeks, including 2 weeks after resolution of parasitemia, may be necessary in highly immunocompromised patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33501959']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33501959'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Severe disease, initial therapy: </i>IV: 7 to 10 mg/kg/dose every 6 to 8 hours in combination with quinine; maximum dose: 600 mg/dose; change to oral clindamycin once symptoms improve (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33501959']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33501959'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ff0a9bc0-9026-40c4-b332-e59da5b10bae">Endocarditis, prophylaxis before invasive dental or respiratory tract procedures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endocarditis, prophylaxis before invasive dental or respiratory tract procedures:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Clindamycin is NOT recommended for prevention of endocarditis in penicillin-allergic patients at high risk due to <i>C. difficile</i> risk; preferred options include cephalexin, azithromycin, clarithromycin, and doxycycline. Recommended only in patients who are at highest risk for infective endocarditis (IE) or adverse outcomes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373317','lexi-content-ref-33853363','lexi-content-ref-28315732']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373317','lexi-content-ref-33853363','lexi-content-ref-28315732'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Limited data available: Oral, IV, IM: 20 mg/kg administered 30 to 60 minutes prior to procedure; maximum dose: 600 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wilson.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wilson.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9938d465-584f-48f7-8083-e90bc984c47e">Exit-site or tunnel infection, peritoneal dialysis catheter</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Exit-site or tunnel infection, peritoneal dialysis catheter:</b> Infant, Children, and Adolescents: Oral: 10 mg/kg/dose 3 times daily; maximum dose: 600 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22851742']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22851742'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="02b4604f-7121-4a88-88dd-a5008cafb941">Intra-abdominal infection, complicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection, complicated:</b>
<b>Note:</b> Not routinely recommended due to <i>Bacteroides fragilis</i> resistance.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: 30 to 40 mg/kg/<b>day</b> divided every 6 to 8 hours in combination with other antibiotics; maximum daily dose: 2,700 mg/<b>day </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-AAP.1','lexi-content-ref-20034345']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-AAP.1','lexi-content-ref-20034345'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="291da3f6-4546-4769-b192-f22ead1b5b60">Malaria, uncomplicated, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Malaria, uncomplicated, treatment (alternative agent): </b>Infants, Children, and Adolescents: Oral: 20 mg/kg/<b>day</b> divided every 8 hours for 7 days in combination with quinine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.3'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5285a396-852e-4b3d-b4b0-d754f216f7be">Osteoarticular infection, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteoarticular infection, acute (eg, septic [bacterial] arthritis, osteomyelitis):</b> Infants, Children, and Adolescents: IV, Oral: 30 to 40 mg/kg/<b>day</b> divided every 6 to 8 hours; maximum dose: IV: 900 mg/dose; Oral: 600 mg/dose. Duration should be individualized based on several factors including causative pathogen, response to therapy, and normalization of inflammatory markers. Minimum total duration is ≥2 to 3 weeks for septic arthritis and ≥3 to 4 weeks for osteomyelitis; longer duration commonly necessary, particularly for infections caused by methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32123023','lexi-content-ref-34350458','lexi-content-ref-28708801']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32123023','lexi-content-ref-34350458','lexi-content-ref-28708801'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a96b8104-65d0-48ba-b460-4308464e6db6">Otitis media, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Otitis media, acute (alternative agent):</b>
<b>Note: </b>Typically reserved for patients who cannot tolerate beta-lactam antibiotics or as an alternative in patients in whom initial therapy for acute otitis media (AOM) fails. In some instances, it may be necessary to use as part of a combination regimen (eg, when activity is desired against <i>Haemophilus influenzae </i>or <i>Moraxella catarrhalis</i>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23439909']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23439909'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months, Children, and Adolescents: Oral: 30 to 40 mg/kg/<b>day</b> divided every 6 to 8 hours; maximum daily dose: 1,800 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23439909','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23439909','lexi-content-ref-AAP.1'])">Ref</a></span>). For patients with severe or recurrent AOM, tympanic membrane perforation, or who are &lt;2 years of age, treat for 10 days; for patients ≥2 years of age with mild to moderate, non-recurrent disease without tympanic membrane perforation, shorter durations of 5 to 7 days may be sufficient (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23439909','lexi-content-ref-28002709','lexi-content-ref-20824827','lexi-content-ref-31876601','lexi-content-ref-NICE.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23439909','lexi-content-ref-28002709','lexi-content-ref-20824827','lexi-content-ref-31876601','lexi-content-ref-NICE.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1762e085-16eb-4d56-91f6-48f0c61ce809">Peritonitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritonitis (peritoneal dialysis):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Prophylaxis in patients receiving peritoneal dialysis</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22851742']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22851742'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">Invasive dental procedures: Oral: 20 mg/kg administered 30 to 60 minutes before procedure; maximum dose: 600 mg.</p>
<p style="text-indent:-2em;margin-left:8em;">GI or genitourinary procedures: IV: 10 mg/kg administered 30 to 60 minutes before procedure; maximum dose: 600 mg.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Treatment:</i> Intraperitoneal, continuous: Loading dose: 300 mg per liter of dialysate; maintenance dose: 125 to 150 mg per liter of dialysate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1','lexi-content-ref-22851742']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1','lexi-content-ref-22851742'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c8f01ae1-8bb4-46b0-a53d-24f5962b66de">
<i>Pneumocystis jirovecii</i> pneumonia, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Pneumocystis jirovecii </i>pneumonia (PCP), treatment (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>HIV-exposed/-infected: </i>
<b>Note:</b> Patients with moderate or severe infection (PaO<sub>2</sub> &lt;70 mm Hg at room air or alveolar-arterial oxygen gradient ≥35 mm Hg) should receive adjunctive glucocorticoids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.3','lexi-content-ref-HHS.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.3','lexi-content-ref-HHS.4'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children: Limited data available: IV, Oral: 10 mg/kg/dose every 6 hours in combination with primaquine for 21 days; maximum IV dose: 600 mg/dose; maximum oral dose: 300 to 450 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.4'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.3'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">Oral: Mild to severe disease: 450 mg every 6 hours <b>or</b> 600 mg every 8 hours in combination with primaquine for 21 days.</p>
<p style="text-indent:-2em;margin-left:8em;">IV: Moderate to severe disease: 600 mg every 6 hours <b>or</b> 900 mg every 8 hours in combination with primaquine for 21 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ed599b2f-52de-47cd-b7d2-d706008b1db0">Pneumonia, community-acquired</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, community-acquired: Note:</b> Duration dependent upon pathogen and clinical course. Typical duration for uncomplicated infections is 5 to 10 days; however, infections caused by MRSA may require longer treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21880587','lexi-content-ref-33683325','lexi-content-ref-32525203']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21880587','lexi-content-ref-33683325','lexi-content-ref-32525203'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥3 months, Children, and Adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21880587']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21880587'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Moderate to severe infection: IV: 40 mg/kg/<b>day</b> divided every 6 to 8 hours; maximum daily dose: 2,700 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">Mild infection or oral step-down therapy: Oral: 30 to 40 mg/kg/<b>day</b> divided every 6 to 8 hours; maximum daily dose: 1,800 mg/<b>day</b>.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1437b55a-5145-4c15-bba4-c28709c37109">Rhinosinusitis, acute bacterial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rhinosinusitis, acute bacterial (alternative agent):</b> Children and Adolescents: Oral: 30 to 40 mg/kg/<b>day</b> divided every 8 hours for 10 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22438350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22438350'])">Ref</a></span>). <b>Note: </b>Use as part of appropriate combination therapy if activity against <i>H. influenzae</i> or <i>M. catarrhalis</i> is desired (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22438350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22438350'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5fe294fd-4626-4e48-9579-84675accedc8">Skin and soft tissue infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection (SSTI):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Impetigo, ecthyma (if MRSA is suspected or confirmed):</i> Oral: 20 mg/kg/<b>day</b> in divided doses every 8 hours for 7 days; maximum dose: 400 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Cellulitis, erysipelas, purulent/fluctuant SSTI: </i>
<b>Note: </b>Typical duration is 5 days for uncomplicated infection but may be extended if clinical response is inadequate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30777258','lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30777258','lexi-content-ref-24947530'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">IV: 25 to 40 mg/kg/<b>day</b> in divided doses every 8 hours; maximum dose: 600 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Oral:</p>
<p style="text-indent:-2em;margin-left:10em;">Methicillin-susceptible <i>Staphylococcus aureus</i> (MSSA) infection: Oral: 25 to 30 mg/kg/<b>day</b> in divided doses every 8 hours; maximum dose: 450 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">MRSA infection: Oral: 30 to 40 mg/kg/<b>day</b> in divided doses every 6 to 8 hours; maximum dose: 450 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Necrotizing soft tissue infections</i>: IV: 10 to 13 mg/kg/dose every 8 hours as part of an appropriate combination regimen in addition to surgical intervention; maximum dose: 900 mg/dose. Continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d3f2098d-7a15-436e-bc6b-422791b57466">
<i>Streptococcus</i>, group A</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Streptococcus, group A:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pharyngitis/tonsillitis (alternative agent for severe penicillin allergy): </i>Children and Adolescents: Oral: 21 mg/kg/<b>day</b> in divided doses every 8 hours for 10 days; maximum dose: 300 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22965026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22965026'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chronic carriage: </i>
<b>Note:</b> Most individuals with chronic carriage do not require antibiotic treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22965026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22965026'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents: Oral: 20 to 30 mg/kg/<b>day</b> in divided doses every 8 hours for 10 days; maximum dose: 300 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22965026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22965026'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fa7b6aef-11c5-4b72-97a0-a39f0f808184">Surgical prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical prophylaxis:</b> Children and Adolescents: IV: 10 mg/kg within 30 to 60 minutes prior to procedure; may repeat dose in 6 hours for prolonged procedure or excessive blood loss; maximum dose: 900 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23327981'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cd360816-1f04-4a66-b502-2527e447fdef">Toxic shock syndrome, toxin production suppression</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Toxic shock syndrome, toxin production suppression (empiric therapy):</b> Infants, Children, and Adolescents: IV: 40 mg/kg/<b>day</b> in divided doses every 6 to 8 hours; maximum dose: 900 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30068739','lexi-content-ref-29858291','lexi-content-ref-23809722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30068739','lexi-content-ref-29858291','lexi-content-ref-23809722'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0e41af1d-f57a-4044-bfa3-84beb015adc1">Toxoplasmosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Toxoplasmosis (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>HIV-exposed/-infected:</i> Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Initial treatment: IV, Oral: 5 to 7.5 mg/kg/dose every 6 hours in combination with pyrimethamine and leucovorin; maximum dose: 600 mg/dose. For congenital toxoplasmosis, continue therapy for 12 months. For acquired toxoplasmosis, continue for ≥6 weeks followed by chronic maintenance therapy; longer duration may be required if incomplete response or extensive disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.3','lexi-content-ref-HHS.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.3','lexi-content-ref-HHS.4'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Chronic maintenance therapy (secondary prophylaxis): Oral: 7 to 10 mg/kg/dose every 8 hours in combination with pyrimethamine and leucovorin; maximum dose: 600 mg/dose. May consider discontinuation when asymptomatic, CD4 percentage is ≥15% (or CD4 count is &gt;200 cells/mm<sup>3</sup> for ages ≥6 years), and the patient has an undetectable HIV viral load in response to antiretroviral therapy for ≥6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.3','lexi-content-ref-HHS.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.3','lexi-content-ref-HHS.4'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51089934"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: </b>Infants, Children, and Adolescents: IV, Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Mild to severe impairment:</b> No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Poorly dialyzed; based on adult information, no supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-5780400']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-5780400'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> Poorly dialyzed; based on adult information, no dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1211913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1211913'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Continuous renal replacement therapy (CRRT):</b> Based on adult information, no dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19397464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19397464'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51089935"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">No adjustment required. Use caution with severe hepatic impairment.</p></div>
<div class="block arsc drugH1Div" id="F56014672"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Antibiotic-associated (non-Clostridioides difficile) diarrhea</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">GI effects range from antibiotic-associated [non-<i>C. difficile</i>]<b> diarrhea</b> (AAD), <b>nausea</b>, and <b>vomiting</b>. Most cases of AAD are mild and self-limiting. However, <i>Clostridioides difficile</i> may account for as many as &gt;20% of cases in children, adolescents, and adults (discussed separately) and result in more severe AAD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27003987','lexi-content-ref-29408016','lexi-content-ref-17385141']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27003987','lexi-content-ref-29408016','lexi-content-ref-17385141'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose- and time-related; antibiotic disruption of indigenous gut microbiota (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-850084','lexi-content-ref-32518780']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-850084','lexi-content-ref-32518780'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; mean time to onset of AAD is 3 to 18 days for adult patients and 2 to 6 days for pediatric patients. The majority of AAD cases occur during (versus after) antibiotic therapy in pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27003987']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27003987'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32518780']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32518780'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Age (pediatric patients &lt;2 years of age and older adults) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27003987','lexi-content-ref-12827001','lexi-content-ref-32518780']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27003987','lexi-content-ref-12827001','lexi-content-ref-32518780'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Length of hospitalization or ICU stay (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30020891','lexi-content-ref-32518780']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30020891','lexi-content-ref-32518780'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of proton pump inhibitor use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32518780']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32518780'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Parenteral nutrition (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30020891']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30020891'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Combinations of antibiotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30020891','lexi-content-ref-31118710']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30020891','lexi-content-ref-31118710'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Clostridioides difficile infection</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Clostridioides</i></b>
<b>
<i>difficile</i> infection</b> (CDI) has occurred, including <b>
<i>Clostridioides difficile</i></b>
<b> associated diarrhea </b>(CDAD) and <b>
<i>Clostridioides difficile</i></b>
<b> colitis</b>. Clindamycin has been associated with a several fold increased risk of CDI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23478961','lexi-content-ref-23620467','lexi-content-ref-31809424','lexi-content-ref-24324224','lexi-content-ref-27216385']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23478961','lexi-content-ref-23620467','lexi-content-ref-31809424','lexi-content-ref-24324224','lexi-content-ref-27216385'])">Ref</a></span>). CDAD must be considered in all patients who present with diarrhea following antibiotic use. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <i>C. difficile</i> should be discontinued if possible. Institute appropriate fluid and electrolyte management, antibiotic treatment of <i>C. difficile</i>, and surgical evaluation as clinically indicated.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose- and time-related; related to cumulative antibiotic exposure. Clindamycin causes disruption of the intestinal microbiota resulting in the overgrowth of pathogens, such as <i>C. difficile</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29462280','lexi-content-ref-21653301']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29462280','lexi-content-ref-21653301'])">Ref</a></span>). In addition, <i>C. difficile</i> is highly resistant to clindamycin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10572152']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10572152'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; may start on the first day of antibiotic therapy or up to 3 months postantibiotic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22146873']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22146873'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Antibiotic exposure (highest risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-21653301','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-21653301','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Type of antibiotic (clindamycin among the highest risk) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23478961','lexi-content-ref-CDC.1','lexi-content-ref-24755188','lexi-content-ref-23620467','lexi-content-ref-31809424','lexi-content-ref-29053792','lexi-content-ref-24324224','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23478961','lexi-content-ref-CDC.1','lexi-content-ref-24755188','lexi-content-ref-23620467','lexi-content-ref-31809424','lexi-content-ref-29053792','lexi-content-ref-24324224','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Long durations in a hospital or other health care setting (recent or current) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Immunocompromised conditions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• A serious underlying condition (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• GI surgery/manipulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Antiulcer medications (eg, proton pump inhibitors and H2 blockers) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Chemotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (immediate and delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity reactions (immediate and delayed) range from <b>maculopapular rash</b> to rare cases of <b>anaphylaxis </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29940315','lexi-content-ref-32577121','lexi-content-ref-31668055']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29940315','lexi-content-ref-32577121','lexi-content-ref-31668055'])">Ref</a></span>). Severe cutaneous adverse reactions (SCARs), including <b>drug reaction with eosinophilia and systemic symptoms</b>, <b>acute generalized exanthematous pustulosis</b>, <b>Stevens-Johnson syndrome</b>, and <b>toxic epidermal necrolysis</b> have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32481338','lexi-content-ref-23165860','lexi-content-ref-7748763','lexi-content-ref-26685211']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32481338','lexi-content-ref-23165860','lexi-content-ref-7748763','lexi-content-ref-26685211'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related; immunologic.</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate hypersensitivity reactions (eg, anaphylaxis): IgE-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-29940315']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-29940315'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Delayed hypersensitivity reactions (eg, maculopapular rash, SCARs), T-cell-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-29940315']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-29940315'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate hypersensitivity reactions (eg, anaphylaxis): Rapid; may occur within an hour of administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32577121']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32577121'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Delayed hypersensitivity reaction: Maculopapular rash: Intermediate; usually 7 to 10 days after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34910281']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34910281'])">Ref</a></span>). Other reactions: Varied; may occur after days to weeks of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29629004','lexi-content-ref-23165860','lexi-content-ref-20843501']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29629004','lexi-content-ref-23165860','lexi-content-ref-20843501'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• HLA-B*51:01 allele in Han Chinese (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27527109']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27527109'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F8008064"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Urticaria, vesiculobullous dermatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b></b>Cardiovascular: Hypotension (following rapid IV administration), thrombophlebitis (IV)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatological: Acute generalized exanthematous pustulosis (Aiempanakit 2020), erythema multiforme, exfoliative dermatitis, maculopapular rash (Dilley 2022), Stevens-Johnson syndrome, Sweet syndrome (Dilley 2022), toxic epidermal necrolysis (Paquet 1995)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: <i>Clostridioides difficile</i>-associated diarrhea (Slimings 2014), <i>Clostridioides difficile</i> colitis (Slimings 2014), diarrhea (Nasiri 2018), dysgeusia (de Groot 2007), esophageal ulcer (Bestari 2019), esophagitis (Bestari 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Vaginitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (Pisciotta 1993), eosinophilia (transient), neutropenia (transient) (Bubalo 2003), pancytopenia (Morales 2014), thrombocytopenia (Morales 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic hepatitis (Aygun 2007)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock (Chiou 2006), anaphylaxis (Paradis 2020, Vilchez-Sánchez 2020), angioedema, drug reaction with eosinophilia and systemic symptoms (Miller Quidley 2012), hypersensitivity angiitis (Fransen 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Abscess at injection site (IM), induration at injection site (IM), irritation at injection site (IM), pain at injection site (IM)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Inflammatory polyarthritis</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (Subedi 2019)</p></div>
<div class="block coi drugH1Div" id="F8008053"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to clindamycin, lincomycin, or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: </i>Additional contraindications (not in US labeling): Oral clindamycin: Infants &lt;30 days of age.</p></div>
<div class="block war drugH1Div" id="F8008062"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal toxicity: Acute kidney injury has been reported; discontinue treatment if clindamycin-induced acute kidney injury is suspected and no other etiology is identified.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Use may result in overgrowth of nonsusceptible organisms, particularly yeast. Should superinfection occur, appropriate measures should be taken as indicated by the clinical situation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• GI disease: Use with caution in patients with a history of GI disease, particularly colitis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with moderate to severe liver disease, however, when administered at every-8-hour intervals, drug accumulation is rare. Monitor hepatic enzymes periodically as dosage adjustments may be necessary in patients with severe liver disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; acute kidney injury may occur, especially if patient is taking other nephrotoxins concurrently.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Atopic patients: Use with caution in atopic patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: A subgroup of older patients with associated severe illness may tolerate diarrhea less well. Monitor carefully for changes in bowel frequency.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tartrazine: Some products may contain tartrazine (FD&amp;C yellow no. 5), which may cause allergic reactions in certain individuals. Allergy is frequently seen in patients who also have an aspirin hypersensitivity.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration (IV): Do not inject IV undiluted as a bolus. Product should be diluted in compatible fluid and infused over 10 to 60 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Not appropriate for use in the treatment of meningitis due to inadequate penetration into the CSF.</p></div>
<div class="block foc drugH1Div" id="F8008168"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as hydrochloride [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cleocin: 75 mg, 150 mg [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c yellow #5 (tartrazine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cleocin: 300 mg [contains fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 75 mg, 150 mg, 300 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as phosphate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cleocin Phosphate: 300 mg/2 mL (2 mL); 600 mg/4 mL (4 mL); 900 mg/6 mL (6 mL); 9 g/60 mL (60 mL) [contains benzyl alcohol, edetate (edta) disodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 300 mg/2 mL (2 mL [DSC]); 600 mg/4 mL (4 mL); 900 mg/6 mL (6 mL); 9000 mg/60 mL (60 mL); 9 g/60 mL (60 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as phosphate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cleocin Phosphate: 300 mg/2 mL (2 mL [DSC]); 600 mg/4 mL (4 mL [DSC]); 900 mg/6 mL (6 mL [DSC]) [contains benzyl alcohol, edetate (edta) disodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 600 mg/50 mL (50 mL); 900 mg/50 mL (50 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as phosphate [strength expressed as base, preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 300 mg/50 mL (50 mL); 600 mg/50 mL (50 mL); 900 mg/50 mL (50 mL); 300 mg/50 mL in NaCl 0.9% (50 mL); 600 mg/50 mL in NaCl 0.9% (50 mL); 900 mg/50 mL in NaCl 0.9% (50 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Oral, as palmitate hydrochloride [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cleocin: 75 mg/5 mL (100 mL) [contains ethylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 75 mg/5 mL (100 mL)</p></div>
<div class="block geq drugH1Div" id="F8008035"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F8008170"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Cleocin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mg (per each): $0.27</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $0.17</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $0.34</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Clindamycin HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mg (per each): $0.72 - $3.60</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $0.18 - $4.20</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $0.54 - $4.80</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Cleocin Phosphate Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">9 g/60 mL (per mL): $0.47</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg/2 mL (per mL): $1.49</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">600 mg/4 mL (per mL): $0.88</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">900 mg/6 mL (per mL): $0.85</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Clindamycin Phosphate in D5W Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg/50 mL (per mL): $0.17 - $0.20</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">600 mg/50 mL (per mL): $0.10 - $0.30</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">900 mg/50 mL (per mL): $0.12 - $0.36</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Clindamycin Phosphate in NaCl Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg/50 mL 0.9% (per mL): $0.17</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">600 mg/50 mL 0.9% (per mL): $0.26</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">900 mg/50 mL 0.9% (per mL): $0.31</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Clindamycin Phosphate Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">9 g/60 mL (per mL): $0.47</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">600 mg/4 mL (per mL): $1.11</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">900 mg/6 mL (per mL): $0.95</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Cleocin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mg/5 mL (per mL): $0.37</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Clindamycin Palmitate HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mg/5 mL (per mL): $0.29 - $1.08</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52869086"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as hydrochloride [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dalacin C: 150 mg, 300 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 150 mg, 300 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dalacin C Phosphate: 150 mg/mL (2 mL, 4 mL, 6 mL, 60 mL) [contains benzyl alcohol, edetate (edta) disodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 150 mg/mL (2 mL, 4 mL, 6 mL, 60 mL, 120 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as phosphate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 300 mg/50 mL ([DSC]); 600 mg/50 mL (50 mL); 900 mg/50 mL (50 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Oral, as palmitate hydrochloride [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dalacin C Palmitate: 75 mg/5 mL (100 mL) [contains ethylparaben]</p></div>
<div class="block adm drugH1Div" id="F8008139"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> Administer undiluted deep IM; rotate sites. Do not exceed 600 mg in a single injection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b>
<b>Never administer undiluted as bolus</b>; administer by IV intermittent infusion over at least 10 to 60 minutes, at a maximum rate of 30 mg/minute (do not exceed 1.2 g/hour).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Capsule should be taken with a full glass of water to avoid esophageal irritation; shake oral solution well before use; may administer with or without meals.</p></div>
<div class="block admp drugH1Div" id="F52614326"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Capsule should be taken with a full glass of water to avoid esophageal irritation. Shake oral solution well before use; solution should be administered using an accurate measuring device (eg, oral syringe). May administer with or without meals.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Administer undiluted deep IM; rotate sites. Do not exceed 600 mg in a single injection.</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Infuse over at least 10 to 60 minutes, at a rate not to exceed 30 mg/minute; hypotension and cardiopulmonary arrest have been reported following rapid IV administration.</p></div>
<div class="block use drugH1Div" id="F8008044"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Bone and joint infections:</b> Treatment of bone and joint infections, including acute hematogenous osteomyelitis caused by <i>Staphylococcus aureus</i> and as adjunctive therapy in the surgical treatment of chronic bone and joint infections caused by susceptible organisms.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Gynecological infections: </b> Treatment of gynecologic infections, including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intraabdominal infections:</b> Treatment of intraabdominal infections, including peritonitis and intraabdominal abscess caused by susceptible anaerobic organisms.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Lower respiratory tract infections:</b> Treatment of lower respiratory tract infections, including pneumonia, empyema, and lung abscess caused by susceptible anaerobes, <i>Streptococcus pneumoniae</i>, other streptococci (except <i>Enterococcus faecalis</i>), and <i>S. aureus</i>.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Septicemia:</b> Treatment of septicemia caused by <i>S. aureus</i>, streptococci (except <i>E. faecalis</i>), and susceptible anaerobes.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection:</b> Treatment of skin and soft tissue infection caused by <i>Streptococcus pyogenes</i>, <i>S. aureus</i>, and susceptible anaerobes.</p></div>
<div class="block off-label drugH1Div" id="F25475290"><span class="drugH1">Use: Off-Label: Adult</span><p>Anthrax; Babesiosis; Bacterial vaginosis; Bite wound infection, prophylaxis of high-risk bite or treatment; Diabetic foot infection, mild to moderate; Gingivitis, acute simple, plaque-associated; Hidradenitis suppurativa; Malaria, treatment; Neutropenic fever, empiric therapy for low-risk cancer patients (alternative agent for penicillin-allergic patients); Pneumocystis jirovecii pneumonia, treatment; Prosthetic joint infection; Rhinosinusitis, acute bacterial; Streptococcal (group A) pharyngitis and chronic carriage; Streptococcus (group B), maternal prophylaxis for prevention of neonatal disease; Surgical prophylaxis; Toxoplasma gondii encephalitis and pneumonitis (treatment/long-term maintenance)</p></div>
<div class="block mst drugH1Div" id="F8007988"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cleocin may be confused with bleomycin, Clinoril, Cubicin, Lincocin</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Clindamycin may be confused with clarithromycin, Claritin, vancomycin, lincomycin</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299057"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F8008069"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Clindamycin (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Clindamycin (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Clindamycin (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Clindamycin (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kaolin: May decrease the absorption of Lincosamide Antibiotics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mecamylamine: Lincosamide Antibiotics may enhance the neuromuscular-blocking effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents: Lincosamide Antibiotics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pectin: May decrease the absorption of Lincosamide Antibiotics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F8008048"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Clindamycin crosses the placenta and can be detected in the cord blood and fetal tissue (Philipson 1973; Weinstein 1976). Clindamycin injection contains benzyl alcohol, which may also cross the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">Clindamycin pharmacokinetics are not affected by pregnancy (Philipson 1976; Weinstein 1976).</p>
<p style="text-indent:0em;margin-top:2em;">Clindamycin is recommended for use in pregnant patients for the prophylaxis of group B streptococcal disease in newborns (alternative option for patients at high risk for anaphylaxis to penicillin [or whose risk is unknown], and who have GBS susceptible to clindamycin) (ACOG 797 2020); prophylaxis and treatment of <i>Toxoplasma gondii</i> encephalitis (alternative therapy), or treatment of <i>Pneumocystis pneumonia</i> (PCP) (alternative therapy) (HHS [OI adult 2020]); bacterial vaginosis (CDC [Workowski 2021]); anthrax (Meaney-Delman 2014); or malaria (CDC 2023). Clindamycin is also one of the antibiotics recommended for prophylactic use prior to cesarean delivery and may be used in certain situations prior to vaginal delivery in patients at high risk for endocarditis (ACOG 199 2018).</p></div>
<div class="block brc drugH1Div" id="F8008052"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Clindamycin is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Clindamycin breast milk concentrations were determined in 5 women immediately postpartum. The dose administered was clindamycin 150 mg by mouth 3 times daily for at least 1 week. Milk was collected over a 6-hour period of time. Maternal serum was collected throughout the study period. Milk concentrations ranged from undetectable (&lt;0.5 mcg/mL) to 3.1 mcg/mL and varied greatly between patients. These concentrations were consistent with the variable maternal serum concentrations of undetectable (&lt;1 mcg/mL) to 33 mcg/mL. The highest breast milk concentrations were observed in the samples from the mothers with the highest serum concentrations (Stéen 1982). Using a milk concentration of 3.1 mcg/mL, the relative infant dose (RID) of clindamycin is 1.2% to 4.7% compared to an infant therapeutic dose of 10 to 40 mg/kg/day, providing an estimated daily infant dose via breast milk of 0.465 mg/kg/day. In general, breastfeeding is considered acceptable when the RID is &lt;10% (Anderson 2016; Ito 2000).</p>
<p style="text-indent:-2em;margin-left:2em;">The manufacturer reports that clindamycin breast milk concentrations range from &lt;0.5 to 3.8 mcg/mL following doses of 150 mg orally to 600 mg IV.</p>
<p style="text-indent:-2em;margin-left:2em;">One case of bloody stools in an infant occurred after a mother received clindamycin while breastfeeding; however, a causal relationship was not confirmed (Mann 1980). In general, antibiotics that are present in breast milk may cause non–dose-related modification of bowel flora.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother; alternative agents may be preferred. Additional guidelines recommend avoiding clindamycin in breastfeeding patients if possible; monitor breastfeeding infants for GI disturbances, diarrhea, and bloody stools if maternal treatment is required (WHO 2002).</p>
<p style="text-indent:-2em;margin-left:2em;">Clindamycin is an alternative antibiotic for the empiric treatment of bacterial mastitis in patients who are breastfeeding. Antibiotic use may be considered when symptoms are present for &gt;24 hours and have not responded to conservative measures, or the patient has symptoms such as fever or tachycardia. Consider a milk culture if symptoms do not improve after 48 hours of antibiotic therapy. The diagnosis of mastitis does not require interruption of breastfeeding (ABM [Mitchell 2022]; WHO 2000).</p></div>
<div class="block mop drugH1Div" id="F8008146"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Observe for changes in bowel frequency. Monitor for colitis and resolution of symptoms. In severe liver disease monitor liver function tests periodically; consider monitoring renal function periodically in patients with renal impairment or taking nephrotoxic medications; during prolonged therapy monitor CBC, liver, and renal function tests periodically.</p></div>
<div class="block pha drugH1Div" id="F8008096"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Reversibly binds to 50S ribosomal subunits preventing peptide bond formation thus inhibiting bacterial protein synthesis; bacteriostatic or bactericidal depending on drug concentration, infection site, and organism</p></div>
<div class="block phk drugH1Div" id="F8008098"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral, hydrochloride: Rapid (90%); clindamycin palmitate must be hydrolyzed in the GI tract before it is active.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Distributed in body fluids and tissues; no significant levels in CSF, even with inflamed meninges.</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates (Gonzalez 2016):</p>
<p style="text-indent:-2em;margin-left:6em;">PMA ≤28 weeks: Median: 1.2 L/kg (range: 0.87 to 2.26 L/kg).</p>
<p style="text-indent:-2em;margin-left:6em;">PMA &gt;28 to 32 weeks: Median: 1.3 L/kg (range: 0.74 to 1.88 L/kg).</p>
<p style="text-indent:-2em;margin-left:6em;">PMA &gt;32 to 40 weeks: Median: 1.03 L/kg (range: 0.7 to 2.12 L/kg).</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates and Infants ≤5 months (PMA &gt;40 to 60 weeks): Median: 0.99 L/kg (range: 0.64 to 1.27 L/kg) (Gonzalez 2016).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants &gt;5 months: Median: 0.83 L/kg (range: 0.7 to 1.17 L/kg) (Gonzalez 2016).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents (Smith 2017):</p>
<p style="text-indent:-2em;margin-left:6em;">Non-obese: Median range: 0.81 to 0.9 L/kg.</p>
<p style="text-indent:-2em;margin-left:6em;">Obese: Median range: 0.86 to 1.03 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 94%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Biologically inactive clindamycin phosphate (intravenous formulation) is rapidly converted to active clindamycin. Clindamycin is metabolized predominantly by CYP3A4, with minor contribution by CYP3A5, to form clindamycin sulfoxide (major metabolite) and N-desmethylclindamycin (minor metabolite).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: ~90%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates (Gonzalez 2016):</p>
<p style="text-indent:-2em;margin-left:6em;">PMA ≤28 weeks: Median: 5.89 hours (range: 2.42 to 12.9 hours).</p>
<p style="text-indent:-2em;margin-left:6em;">PMA &gt;28 to 32 weeks: Median: 5.25 hours (range: 2.34 to 8.87 hours).</p>
<p style="text-indent:-2em;margin-left:6em;">PMA &gt;32 to 40 weeks: Median: 3.96 hours (range: 1.3 to 8.83 hours).</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates and Infants ≤5 months (Gonzalez 2016): PMA &gt;40 to 60 weeks: Median: 2.35 hours (range: 0.94 to 6.44 hours).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants &gt;5 months to 1 year (Gonzalez 2016): Median: 2.05 hours (range: 1.26 to 3.47 hours).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents (Smith 2017):</p>
<p style="text-indent:-2em;margin-left:6em;">Non-obese: Median range: 2.15 to 2.84 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Obese: Median range: 2.15 to 3.55 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 3 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Elderly (oral) ~4 hours (range: 3.4 to 5.1 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Oral: Within 60 minutes; IM: 1 to 3 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~10%) and feces (3.6%) as active drug and metabolites.</p></div>
<div class="block phksp drugH1Div" id="F58339693"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Anti-infective considerations:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with efficacy:</i> AUC<sub>24</sub>/minimum inhibitory concentration (MIC), goal: ≥ ~27 (LaPlante 2008; Levison 2009; Muller 2010).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Expected drug exposure in normal renal function:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>C</b>
<b>
<sub>max </sub></b>
<b>(peak): </b>Steady state:</p>
<p style="text-indent:-2em;margin-left:8em;">Neonates (preterm and term) and Infants &lt;4 months of age: IV: Median dose 15 mg/kg/<b>day </b>in divided doses: ~7.9 to 8.9 mg/L (Greenberg 2020).</p>
<p style="text-indent:-2em;margin-left:8em;">Children 2 to 6 years of age: IV: 12 mg/kg/dose every 8 hours: 14.1 mg/L (Smith 2017).</p>
<p style="text-indent:-2em;margin-left:8em;">Children &gt;6 years and Adolescents: IV: 10 mg/kg/dose every 8 hours: 12.2 mg/L (Smith 2017).</p>
<p style="text-indent:-2em;margin-left:8em;">Adults: IV: 600 mg every 6 or 8 hours: 12.2 mg/dL (Flaherty 1988; Smith 2017).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>AUC<sub>0-24</sub></b>
<b>
<sub></sub></b>
<b>(total): </b>Steady state:</p>
<p style="text-indent:-2em;margin-left:8em;">Neonates (preterm and term) and Infants &lt;4 months of age: IV: Median dose 15 mg/kg/<b>day </b>in divided doses: 8.3 mg/L: 96 mg•hour/L (Greenberg 2020).</p>
<p style="text-indent:-2em;margin-left:8em;">Children 2 to 6 years of age: IV: 12 mg/kg/dose every 8 hours: 132.6 mg•hour/L (Smith 2017).</p>
<p style="text-indent:-2em;margin-left:8em;">Children &gt;6 years of age: IV: 10 mg/kg/dose every 8 hours: 134.4 mg•hour/L (Smith 2017).</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents: IV 10 mg/kg/dose every 8 hours: 145.8 mg•hour/L (Smith 2017).</p>
<p style="text-indent:-2em;margin-left:8em;">Adults: IV: 600 mg every 6 to 8 hours: 105.6 to 134.1 mg•hour/L (Flaherty 1988; Smith 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postantibiotic effect: </i>Varies based on the organism and antimicrobial exposure (concentration and duration):</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Bacillus anthracis: </i>2 hours (Athamna 2004).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>S. aureus</i>: Mean: 1.7 to 4 hours (range: 0.4 to 6.7 hours) (Xue 1996).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Streptococcus pneumoniae: ~</i>1 to 6.9 hours (Kuenzi 1987).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>S. pyogenes: </i>~1 to 5.5 hours (Kuenzi 1987).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F10961961"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Dalacin c</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Clidan | Clindalaf | Clindamicina | Clindamicina pharmavial | Clindamicina richet | Dalacin c | Dexacne | Microbion | Resbiotic</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Clindac | Clindac Sandoz | Clindamycin | Clindamycin 1a pharma gmbh | Clindamycin lannacher | Clindamycin sandoz | Clindamycin stada | Dalacin c | Lanacine</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo-clindamycin | Calindamin | Chemmart clindamycin | Cleocin | Clindamycin | Clindamycin bnm | Clindamycin link | Clindamycin lu | Clindamyk | Dalacin c | Terry white chemists clindamycin</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Anobac | Cinamycin | Cleocin | Cleodin | Climed | Climycin | Clinacyn | Clindacin | Clindamet | Clindax | Clinex | Daclin | Dalacin | Endamycin | Fortior | Lincocin | Lindamax | Qcin | Riboclin | Xindal</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Clindamycin sandoz | Clindamycine EG | Dalacin</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Dalacine</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Clindamycin | Clindamycin abr | Clindamycin mip | Daclyne | Dalacin c | Klimicin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Clindabiotic | Clindamicil | Clindamin c | Clindarix | Cloridrato de clindamicina | Dalacin c</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Clindamycin mepha | Clindamycin pfizer | Clindamycin sandoz | Clindamycin Zentiva | Dalacin c</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Biomicin | Dalacin c</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Clindamycin | Dalacin c | De bao sheng | Fu si ka | Hai mai ke | Hu yi | Jing dan | Ke er sheng | Ke lin mei | Lizhu ling | She yue | Shuai jie | Suo ning | Ta di xian | Tang ni wei | Te li xian | Xin fu</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Acniben | Baclin | Clinbac | Clindacil | Clindamicina | Dalacin c | Damicine | Damiclin | Euroclin</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Dalacin | Dalacin c | Klimicin | Klindamycin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Aclinda | Clin sanorania | Clinda 1a pharma | Clinda lich | Clindabeta | Clindadura | Clindahexal | Clindalind | Clindamycin | Clindamycin 1a pharma | Clindamycin abz | Clindamycin Acis | Clindamycin al | Clindamycin aristo | Clindamycin Billix | Clindamycin dura | Clindamycin holsten | Clindamycin klast | Clindamycin ratiopharm | Clindamycin sandoz | Clindamycin von CT | Clindastad | Clindatop | Dalacin | Dentomycin | Sobelin | Turimycin</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Dalacin</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Clindamicina | Clindamicina mk | Clindaris | Daltrex | Euroclin | Globacin</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Clindamicina | Clindamicina mk | Cluvax | Dalacin c | Dalacin C Fosfato | Euroclin</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Clindamycin | Dalacin c | Klimicin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Clinacyn | Clindacin | Clindacine | Clindam | Clindariv | Clindatech | Dalacin c | Mepaclind</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Clindamicina qualigen | Dalacin</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Cindi 150 | Clindamycin abr | Dalacin c</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Clindamycin orion | Clindamycin sandoz | Clindamycin SanoSwiss | Dalacin | Klindagol</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Clindamycine mylan | Dalacine</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Clindamycin | Clindamycin sandoz | Dalacin c</span>;</li>
<li>
<span class="countryCode">(GH)</span> <span class="country">Ghana</span><span class="countrySeparator">: </span><span class="drugName">C cin | Dacillin | Entracin | Kinamycin | Klinda 150</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Dalacin c</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">B.b | Climadan | Clindamycin rivopharm | Dalacin c</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Dalacin c | Klimicin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Dalacin | Dalacin c | Klimicin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Albiotin | Anerocid | Biodasin | Cindala | Clidacor | Climadan | Clinatic | Clinbercin | Clindamycin | Clindexin | Clinex | Clinidac | Clinika | Clinium | Clinjos | Clinmas | Comdasin | Dacin | Daclin | Dalacin c | Ethidan | Indanox | Lando | Librodan | Lindacyn | Lindan | Milorin | Niladacin | Nufaclind | Opiclam | Probiotin | Prolic | Xeldac | Zumatic</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Clindamycin | Dalacin c</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Dalacin | Dalacin c</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Clid | Clin | Clincin | Clindaness | Clindanol | Clindaset | Clindasure | Clindatec | Clindatime | Clindol | Clingram | Clinsof | Clinviva | Clinzucia | Cliza | Dalacin c | Dalcap | Dalcinex | Egyclin | Hiclinamycin | Muclin</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Dalacin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Dalacin c</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Clinaram | Clindacin | Clindamyl | Clindox | Clinimycin | Dalacin c | Lanacin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Dalacin</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Bergclin | Cindi 150 | Cindi 300 | Clindacin | Clindar b | Clindazed | Dacibact | Dacillin | Dalacin | Dalacin c</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cleocin | Clicin | Climycin | Clindacin | Dongkoo clindamycin | Fullgram | Mothers clindamycin | Neotacin | Withus clindamycin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Dalacin c | Dalacin palmitate</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Dalacin | Dalacin c | Danalli | Torgyn</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Clindamycin | Dalacin | Dalacin c | Klimicin | Klindamycin</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Clindamycine EG | Dalacin</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Clindamycin | Dalacin | Dalacin c | Klimicin | Klindamycin</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Dalacine</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Amonadin | Ancine | Apomiclin | Cigmadil | Clendix | Clinamsa | Clindamicin | Clindamicina | Clindamicina avivia | Clindamicina gi se | Clindamicina kendr | Clindamicina le gi | Clindamicina Raam | Clindazyn | Cliran | Croci | Dalacin c | Dalacin c rtu | Dalafar | Destralina | Drastep | Foshlenn | Indacil | Indamid | Indamid dx | Klamoxyl | Klin amsa | Lindacil | Lisiken | Losertrin | Lyrfhis | Midacyn | Noclin | Tanzanita | Ulmicy</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Clindac | Dalacin c | Klindam | Lindacin | Tidact</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Clamysol | Dalacin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Clindamycine | Dalacin | Dalacin c</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Cleocin | Clindamycin | Clindamycin villerton | Dalacin | Dalacin c | Sobelin</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Clindamycin Abm | Dalacin c</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Clendabrax | Clincheck | Clinda C | Clindabiot | Clindabiotech | Clindacin | Clindamax | Clindamed | Clindamicina | Clindapharm | Clindasted | Clindess | Dalacin c | Damizit | Euroclin | Inkabiotic | Kilacinox</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Abanxl | Acresil | Anerocin | Biogenerics clindamycin | Climaxin | Clin d | Clin gen | Clindacin | Clindacyn | Clindagen | Clindagold | Clindal | Clindamycin | Clindamycin Pacific | Clindamycin sandoz | Clinmicap | Dacin | Daklin | Dalacin c | Dalamax | Dalamed | Dynacin | Indanox | Indimax | Inprosyn-hp | Klindex | Kylezine | May clindamycin | Myclin | Peldacyn | Pharex Clindamycin | Potecin | Promeclin | Ritemed Clindamycin | Robecren | Tidact | Vagilin | Zindal | Zynamycin</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Clindacure | Clindamycin | Dalacin c | Serind | Uniclin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Clindacin | Clindamycin | Clindo | Dalacin c | Klimicin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Camyda | Cleocin | Cleocin phosphate | Clindamycin HCL | Clindamycin in 5% dextrose | Clindamycin injection in 5% dextrose</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Clincina | Clindamicina | Clindamicina atral | Clindamicina labesfal | Dalacin c</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Clindamicina dallas | Clindamicina prosalud | Cluvax</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Clindacin | Clinimycin | Dalacin C | Dalacin C (IV/IM) | Dalacin C Granules | Klindaver | Lanacin</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Clindacin | Dalacin c</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Clindacin | Clindafer | Clindamycin | Dalacin c | Klinoksin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo-clindamycin | Clindamycin | Dalacin c</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Clindamycin | Clindamycin actavis | Clindamycin alternova | Clindamycin bijon | Clindamycin Orifarm | Clindamycin villerton | Dalacin | Klindamycin ebb</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Dalacin c | Tidact</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Dalacin | Dalacin c | Klimicin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Dalacin | Dalacin c | Klimicin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Acnocin | Clinda | Clinda p | Clindacap | Clindaman | Clindarax | Clindastar | Clindin | Clinott | Dacin-f | Dalacin c | Klimicin | Klinda rx | Klindamycin | Millda | Rosil | Todacin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Dalacine</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Cleocin | Clin | Klindan | Klinoksin | Klitopsin | Meneklin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">B.b | Bibi u | Cledomycin | Cleocin | Clicin | Clincin | Clindamycin | Clindamycin Patron | Dalcine | Damicin | Kanolin | Kingdacin | Kojarclinda | Lindacin | Tidact | Ulecin | Vicin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Clindahexal | Clindamycin | Dalacin c | Klimicin | Ultrex</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Zeemycin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Clinda | Clinda pediatrico | Clindamicina | Dalacin c</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Clindacin | Clindamicina | Clindox | Dalacin</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Cledamed | Clindamark | Fabaclin c | Flamiclinda | Kamicingsv | Nakai | Pyclin | Zurer</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Clindahexal | Dalacin c</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Clindahexal | Dalacin c</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Dalacin c</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-14529001">
<a name="14529001"></a>ADA Division of Legal Affairs. A legal perspective on antibiotic prophylaxis. <i>J Am Dent Assoc.</i> 2003;134(9):1260.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/14529001/pubmed" id="14529001" target="_blank">14529001</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32481338">
<a name="32481338"></a>Aiempanakit K, Apinantriyo B. Clindamycin-induced acute generalized exanthematous pustulosis: a case report. <i>Medicine (Baltimore)</i>. 2020;99(21):e20389. doi:10.1097/MD.0000000000020389<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/32481338/pubmed" id="32481338" target="_blank">32481338</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30872149">
<a name="30872149"></a>Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part II: topical, intralesional, and systemic medical management. <i>J Am Acad Dermatol</i>. 2019;81(1):91-101. doi:10.1016/j.jaad.2019.02.068<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/30872149/pubmed" id="30872149" target="_blank">30872149</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14759242">
<a name="14759242"></a>Allewelt M, Schüler P, Bölcskei PL, Mauch H, Lode H; Study Group on Aspiration Pneumonia. Ampicillin + sulbactam vs clindamycin +/- cephalosporin for the treatment of aspiration pneumonia and primary lung abscess. <i>Clin Microbiol Infect</i>. 2004;10(2):163-170. doi:10.1111/j.1469-0691.2004.00774.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/14759242/pubmed" id="14759242" target="_blank">14759242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021-2024 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31977795">
<a name="31977795"></a>American College of Obstetricians and Gynecologists (ACOG). Prevention of group B streptococcal early-onset disease in newborns: ACOG committee opinion, number 797. <i>Obstet Gynecol</i>. 2020;135(2):e51‐e72. doi:10.1097/AOG.0000000000003668<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/31977795/pubmed" id="31977795" target="_blank">31977795</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12892448">
<a name="12892448"></a>American Dental Association, American Academy of Orthopedic Surgeons. Antibiotic prophylaxis for dental patients with total joint replacements. <i>J Am Dent Assoc.</i> 2003;134(7):895-899.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/12892448/pubmed" id="12892448" target="_blank">12892448</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15127872">
<a name="15127872"></a>American Dental Association Council on Scientific Affairs. Combating antibiotic resistance. <i>J Am Dent Assoc.</i> 2004;135(4):484-487.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/15127872/pubmed" id="15127872" target="_blank">15127872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24799638">
<a name="24799638"></a>Anderson DJ, Podgorny K, Berríos-Torres SI, et al. Strategies to prevent surgical site infections in acute care hospitals: 2014 update. <i>Infect Control Hosp Epidemiol</i>. 2014;35(6):605-627. doi: 10.1086/676022.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/24799638/pubmed" id="24799638" target="_blank">24799638</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children.</i> 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14998982">
<a name="14998982"></a>Athamna A, Athamna M, Medlej B, Bast DJ, Rubinstein E. In vitro post-antibiotic effect of fluoroquinolones, macrolides, beta-lactams, tetracyclines, vancomycin, clindamycin, linezolid, chloramphenicol, quinupristin/dalfopristin and rifampicin on Bacillus anthracis. <i>J Antimicrob Chemother.</i> 2004;53(4):609-615. doi:10.1093/jac/dkh130<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/14998982/pubmed" id="14998982" target="_blank">14998982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17879418">
<a name="17879418"></a>Aygun C, Kocaman O, Gurbuz Y, Senturk O, Hulagu S. Clindamycin-induced acute cholestatic hepatitis. <i>World J Gastroenterol</i>. 2007;13(40):5408-5410. doi:10.3748/wjg.v13.i40.5408<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/17879418/pubmed" id="17879418" target="_blank">17879418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Berbari.2019">
<a name="Berbari.2019"></a>Baddour LM, Chen AF. Prosthetic joint infection: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 27, 2023a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baddour.1">
<a name="Baddour.1"></a>Baddour LM, Harper M. Animal bites (dogs, cats, and other mammals): Evaluation and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 27, 2023b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baddour.2">
<a name="Baddour.2"></a>Baddour LM, Harper M. Human bites: evaluation and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 27, 2021b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baddour.3">
<a name="Baddour.3"></a>Baddour LM. Impetigo. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 1, 2023c.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18649613">
<a name="18649613"></a>Bader MS. Diabetic foot infection. <i>Am Fam Physician</i>. 2008;78(1):71-79.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/18649613/pubmed" id="18649613" target="_blank">18649613</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26373317">
<a name="26373317"></a>Baltimore RS, Gewitz M, Baddour LM, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young and the Council on Cardiovascular and Stroke Nursing. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation.</i> 2015;132(15):1487-1515. doi:10.1161/CIR.0000000000000298<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/26373317/pubmed" id="26373317" target="_blank">26373317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-expert.1">
<a name="expert.1"></a>Based on expert opinion.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26229122">
<a name="26229122"></a>Berbari EF, Kanj SS, Kowalski TJ, et al; Infectious Diseases Society of America. 2015 Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. <i>Clin Infect Dis</i>. 2015;61(6):e26-e46. doi: 10.1093/cid/civ482.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/26229122/pubmed" id="26229122" target="_blank">26229122</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28467526">
<a name="28467526"></a>Berríos-Torres SI, Umscheid CA, Bratzler DW, et al; Healthcare Infection Control Practices Advisory Committee. Centers for Disease Control and Prevention guideline for the prevention of surgical site infection, 2017. <i>JAMA Surg</i>. 2017;152(8):784-791. doi: 10.1001/jamasurg.2017.0904.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/28467526/pubmed" id="28467526" target="_blank">28467526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31903026">
<a name="31903026"></a>Bestari MB, Agustanti N, Abdurachman SA. Clindamycin-induced esophageal injury: is it an underdiagnosed entity? <i>Clin Med Insights Case Rep</i>. 2019;12:1179547619884055. doi:10.1177/1179547619884055<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/31903026/pubmed" id="31903026" target="_blank">31903026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30558872">
<a name="30558872"></a>Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/30558872/pubmed" id="30558872" target="_blank">30558872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bow.2018">
<a name="Bow.2018"></a>Bow E. Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 20, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31834290">
<a name="31834290"></a>Bower WA, Schiffer J, Atmar RL, et al; CDC ACIP Anthrax Vaccine Work Group. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices, 2019. <i>MMWR Recomm Rep</i>. 2019;68(4):1-14. doi:10.15585/mmwr.rr6804a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/31834290/pubmed" id="31834290" target="_blank">31834290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21880587">
<a name="21880587"></a>Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2011;53(7):e25-e76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/21880587/pubmed" id="21880587" target="_blank">21880587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.1">
<a name="Bradley.1"></a>Bradley JS, Nelson JD, Barnett ED, et al, eds. <i>Nelson's Pediatric Microbial Therapy</i>. 27th ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24777226">
<a name="24777226"></a>Bradley JS, Peacock G, Krug SE, et al; AAP Committee on Infectious Diseases and Disaster Preparedness Advisory Council. Pediatric anthrax clinical management. <i>Pediatrics</i>. 2014;133(5):e1411-e1436. doi: 10.1542/peds.2014-0563.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/24777226/pubmed" id="24777226" target="_blank">24777226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23327981">
<a name="23327981"></a>Bratzler DW, Dellinger EP, Olsen KM, et al; American Society of Health-System Pharmacists; Infectious Diseases Society of America; Surgical Infection Society; Society for Healthcare Epidemiology of America. Clinical practice guidelines for antimicrobial prophylaxis in surgery. <i>Am J Health Syst Pharm. </i>2013;70(3):195-283.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/23327981/pubmed" id="23327981" target="_blank">23327981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23478961">
<a name="23478961"></a>Brown KA, Khanafer N, Daneman N, Fisman DN. Meta-analysis of antibiotics and the risk of community-associated <i>Clostridium difficile</i> infection. <i>Antimicrob Agents Chemother</i>. 2013;57(5):2326-2332. doi:10.1128/AAC.02176-12<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/23478961/pubmed" id="23478961" target="_blank">23478961</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12523467">
<a name="12523467"></a>Bubalo JS, Blasdel CS, Bearden DT. Neutropenia after single-dose clindamycin for dental prophylaxis. <i>Pharmacotherapy</i>. 2003;23(1):101-103. doi:10.1592/phco.23.1.101.31920<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/12523467/pubmed" id="12523467" target="_blank">12523467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention (CDC). FAQs for clinicians about <i>C. diff</i>. Updated March 27, 2020. Accessed July 27, 2021. <a href="https://www.cdc.gov/cdiff/clinicians/faq.html" target="_blank">https://www.cdc.gov/cdiff/clinicians/faq.html</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control and Prevention (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2">
<a name="CDC.2"></a>Centers for Disease Control and Prevention (CDC). Treatment of malaria (guidelines for clinicians 2019). <a href="https://www.cdc.gov/malaria/resources/pdf/clinicalguidance.pdf" target="_blank">http://www.cdc.gov/malaria/resources/pdf/clinicalguidance.pdf</a>. Published July 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.3">
<a name="CDC.3"></a>Centers for Disease Control and Prevention (CDC). Treatment of malaria: guidelines for clinicians (United States). <a href="https://www.cdc.gov/malaria/diagnosis_treatment/clinicians1.html" target="_blank">https://www.cdc.gov/malaria/diagnosis_treatment/clinicians1.html</a>. Updated June 28, 2023. Accessed July 26, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Chen.2018">
<a name="Chen.2018"></a>Chen KT. Postpartum endometritis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 27, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17116619">
<a name="17116619"></a>Chiou CS, Lin SM, Lin SP, Chang WG, Chan KH, Ting CK. Clindamycin-induced anaphylactic shock during general anesthesia. <i>J Chin Med Assoc</i>. 2006;69(11):549-551. doi:10.1016/S1726-4901(09)70327-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/17116619/pubmed" id="17116619" target="_blank">17116619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22438350">
<a name="22438350"></a>Chow AW, Benninger MS, Brook I, et al; Infectious Diseases Society of America. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. <i>Clin Infect Dis.</i> 2012;54(8):e72-e112.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/22438350/pubmed" id="22438350" target="_blank">22438350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Chow.2018">
<a name="Chow.2018"></a>Chow AW. Complications, diagnosis, and treatment of odontogenic infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 9, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Chu.2019">
<a name="Chu.2019"></a>Chu VH. Staphylococcal toxic shock syndrome. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 23, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5780400">
<a name="5780400"></a>Cimino JE, Tierno PM Jr. Hemodialysis properties of clindamycin (7-chloro-7-deoxylincomycin). <i>Appl Microbiol</i>. 1969;17(3):446-448.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/5780400/pubmed" id="5780400" target="_blank">5780400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cleocin.1">
<a name="Cleocin.1"></a>Cleocin hydrochloride capsules (clindamycin) [prescribing information]. New York, NY: Pfizer; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cleocin.2">
<a name="Cleocin.2"></a>Cleocin Pediatric granule (clindamycin) [prescribing information]. New York, NY: Pharmacia &amp; Upjohn Co; February 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cleocin.3">
<a name="Cleocin.3"></a>Cleocin Pediatric oral solution, USP (clindamycin) [prescribing information]. New York, NY: Pharmacia &amp; Upjohn Company LLC; January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cleocin.4">
<a name="Cleocin.4"></a>Cleocin Pediatric oral solution (clindamycin) [prescribing information]. New York, NY: Pharmacia &amp; Upjohn Co LLC; February 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cleocin.5">
<a name="Cleocin.5"></a>Cleocin phosphate injection (clindamycin) [prescribing information]. New York, NY: Pharmacia &amp; Upjohn Co LLC; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Clindamycin.1">
<a name="Clindamycin.1"></a>Clindamycin Phosphate in Sodium Chloride injection [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24755188">
<a name="24755188"></a>Collins CE, Ayturk MD, Flahive JM, Emhoff TA, Anderson FA Jr, Santry HP. Epidemiology and outcomes of community-acquired <i>Clostridium difficile</i> infections in Medicare beneficiaries. <i>J Am Coll Surg</i>. 2014;218(6):1141-1147.e1. doi:10.1016/j.jamcollsurg.2014.01.053<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/24755188/pubmed" id="24755188" target="_blank">24755188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dalacin.1">
<a name="Dalacin.1"></a>Dalacin C (clindamycin) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17635503">
<a name="17635503"></a>de Groot MC, van Puijenbroek EP. Clindamycin and taste disorders. <i>Br J Clin Pharmacol</i>. 2007;64(4):542-545. doi:10.1111/j.1365-2125.2007.02908.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/17635503/pubmed" id="17635503" target="_blank">17635503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23620467">
<a name="23620467"></a>Deshpande A, Pasupuleti V, Thota P, et al. Community-associated <i>Clostridium difficile</i> infection and antibiotics: a meta-analysis. <i>J Antimicrob Chemother</i>. 2013;68(9):1951-1961. doi:10.1093/jac/dkt129<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/23620467/pubmed" id="23620467" target="_blank">23620467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27753139">
<a name="27753139"></a>Dessinioti C, Zisimou C, Tzanetakou V, Stratigos A, Antoniou C. Oral clindamycin and rifampicin combination therapy for hidradenitis suppurativa: a prospective study and 1-year follow-up. <i>Clin Exp Dermatol</i>. 2016;41(8):852-857. doi: 10.1111/ced.12933.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/27753139/pubmed" id="27753139" target="_blank">27753139</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30068739">
<a name="30068739"></a>Dietrich ML, Steele RW. Group A <i>Streptococcus</i>. <i>Pediatr Rev</i>. 2018;39(8):379-391. doi:10.1542/pir.2017-0207<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/30068739/pubmed" id="30068739" target="_blank">30068739</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34910281">
<a name="34910281"></a>Dilley M, Geng B. Immediate and delayed hypersensitivity reactions to antibiotics: aminoglycosides, clindamycin, linezolid, and metronidazole. <i>Clin Rev Allergy Immunol</i>. 2022;62(3):463-475. doi:10.1007/s12016-021-08878-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/34910281/pubmed" id="34910281" target="_blank">34910281</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dixon.1">
<a name="Dixon.1"></a>Dixon JM. Lactational mastitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 2, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32123023">
<a name="32123023"></a>Donaldson N, Sanders J, Child J, Parker S. Acute hematogenous bacterial osteoarticular infections in children. <i>Pediatr Rev</i>. 2020;41(3):120-136. doi:10.1542/pir.2018-0201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/32123023/pubmed" id="32123023" target="_blank">32123023</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31809424">
<a name="31809424"></a>Duffy CR, Huang Y, Andrikopoulou M, et al. Clindamycin, gentamicin, and risk of <i>Clostridium difficile</i> infection and acute kidney injury during delivery hospitalizations. <i>Obstet Gynecol</i>. 2020;135(1):59-67. doi:10.1097/AOG.0000000000003568<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/31809424/pubmed" id="31809424" target="_blank">31809424</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29940315">
<a name="29940315"></a>Ebo DG, Mertens C, Braes M, Mennes I, Bridts CH, Sabato V. Clindamycin anaphylaxis confirmed by in vivo and in vitro testing. <i>J Allergy Clin Immunol Pract</i>. 2019;7(1):331-333. doi:10.1016/j.jaip.2018.06.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/29940315/pubmed" id="29940315" target="_blank">29940315</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3245695">
<a name="3245695"></a>Flaherty JF, Rodondi LC, Guglielmo BJ, Fleishaker JC, Townsend RJ, Gambertoglio JG. Comparative pharmacokinetics and serum inhibitory activity of clindamycin in different dosing regimens. <i>Antimicrob Agents Chemother.</i> 1988;32(12):1825-1829. doi:10.1128/AAC.32.12.1825<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/3245695/pubmed" id="3245695" target="_blank">3245695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33332861">
<a name="33332861"></a>Fransen M, Verstraeten VLRM. Cutaneous vasculitis caused by clindamycin. <i>Dermatitis</i>. 2021;32(6):e100-e101. doi:10.1097/DER.0000000000000665<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/33332861/pubmed" id="33332861" target="_blank">33332861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21258094">
<a name="21258094"></a>Freifeld AG, Bow EJ, Sepkowitz KA, et al; Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2011;52(4):e56-e93. doi: 10.1093/cid/cir073.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/21258094/pubmed" id="21258094" target="_blank">21258094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8866384">
<a name="8866384"></a>Gall S, Koukol DH. Ampicillin/sulbactam vs. clindamycin/gentamicin in the treatment of postpartum endometritis. <i>J Reprod Med</i>. 1996;41(8):575-580.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/8866384/pubmed" id="8866384" target="_blank">8866384</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30777258">
<a name="30777258"></a>Galli L, Venturini E, Bassi A, et al. Common community-acquired bacterial skin and soft-tissue infections in children: an intersociety consensus on impetigo, abscess, and cellulitis treatment. <i>Clin Ther</i>. 2019;41(3):532-551.e17. doi:10.1016/j.clinthera.2019.01.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/30777258/pubmed" id="30777258" target="_blank">30777258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19590173">
<a name="19590173"></a>Gener G, Canoui-Poitrine F, Revuz JE, et al. Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients. <i>Dermatology</i>. 2009;219(2):148-154. doi: 10.1159/000228334.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/19590173/pubmed" id="19590173" target="_blank">19590173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Goldenberg.2019">
<a name="Goldenberg.2019"></a>Goldenberg DL, Sexton DJ. Septic arthritis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 1, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26926644">
<a name="26926644"></a>Gonzalez D, Delmore P, Bloom BT, et al. Clindamycin pharmacokinetics and safety in preterm and term infants. <i>Antimicrob Agents Chemother</i>. 2016;60(5):2888-2894.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/26926644/pubmed" id="26926644" target="_blank">26926644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31725114">
<a name="31725114"></a>Greenberg RG, Wu H, Maharaj A, et al. A pharmacoepidemiologic study of the safety and effectiveness of clindamycin in infants. <i>Pediatr Infect Dis J.</i> 2020;39(3):204-210. doi:10.1097/INF.0000000000002524<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/31725114/pubmed" id="31725114" target="_blank">31725114</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26831295">
<a name="26831295"></a>Gulliver W, Zouboulis CC, Prens E, Jemec GB, Tzellos T. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa. <i>Rev Endocr Metab Disord</i>. 2016;17(3):343-351. doi: 10.1007/s11154-016-9328-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/26831295/pubmed" id="26831295" target="_blank">26831295</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8722544">
<a name="8722544"></a>Hall G, Nord CE, Heimdahl A. Elimination of bacteraemia after dental extraction: comparison of erythromycin and clindamycin for prophylaxis of infective endocarditis. <i>J Antimicrob Chemother</i>. 1996;37(4):783-795.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/8722544/pubmed" id="8722544" target="_blank">8722544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26785402">
<a name="26785402"></a>Harris AM, Hicks LA, Qaseem A; High Value Care Task Force of the American College of Physicians and for the Centers for Disease Control and Prevention. Appropriate antibiotic use for acute respiratory tract infection in adults: advice for high-value care from the American College of Physicians and the Centers for Disease Control and Prevention. <i>Ann Intern Med.</i> 2016;164(6):425-434. doi: 10.7326/M15-1840.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/26785402/pubmed" id="26785402" target="_blank">26785402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19397464">
<a name="19397464"></a>Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. <i>Pharmacotherapy</i>. 2009;29(5):562-577. doi: 10.1592/phco.29.5.562.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/19397464/pubmed" id="19397464" target="_blank">19397464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24447897">
<a name="24447897"></a>Hendricks KA, Wright ME, Shadomy SV, et al; Workgroup on Anthrax clinical guidelines. Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults. <i>Emerg Infect Dis</i>. 2014;20(2):e130687. doi: 10.3201/eid2002.130687.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/24447897/pubmed" id="24447897" target="_blank">24447897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22146873">
<a name="22146873"></a>Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ. Time interval of increased risk for <i>Clostridium difficile</i> infection after exposure to antibiotics. <i>J Antimicrob Chemother</i>. 2012;67(3):742-748. doi:10.1093/jac/dkr508<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/22146873/pubmed" id="22146873" target="_blank">22146873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22527064">
<a name="22527064"></a>Hicks CW, Sweeney DA, Cui X, Li Y, Eichacker PQ. An overview of anthrax infection including the recently identified form of disease in injection drug users. <i>Intensive Care Med.</i> 2012;38(7):1092-1104.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/22527064/pubmed" id="22527064" target="_blank">22527064</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28002709">
<a name="28002709"></a>Hoberman A, Paradise JL, Rockette HE, et al. Shortened antimicrobial treatment for acute otitis media in young children. <i>N Engl J Med</i>. 2016;375(25):2446-2456. doi:10.1056/NEJMoa1606043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/28002709/pubmed" id="28002709" target="_blank">28002709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23457071">
<a name="23457071"></a>Jevsevar DS, Abt E. The New AAOS-ADA clinical practice guideline on prevention of orthopaedic implant infection in patients undergoing dental procedures. <i>J Am Acad Orthop Surg.</i> 2013;21(3):195-197.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/23457071/pubmed" id="23457071" target="_blank">23457071</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10572152">
<a name="10572152"></a>Johnson S, Samore MH, Farrow KA, et al. Epidemics of diarrhea caused by a clindamycin-resistant strain of <i>Clostridium difficile</i> in four hospitals. <i>N Engl J Med</i>. 1999;341(22):1645-1651. doi:10.1056/NEJM199911253412203<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/10572152/pubmed" id="10572152" target="_blank">10572152</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kanafani.2018">
<a name="Kanafani.2018"></a>Kanafani ZA. Invasive Cutibacterium (formerly Propionibacterium) infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 27, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29629004">
<a name="29629004"></a>Karakayalı B, Yazar AS, Çakir D, et al. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome associated with cefotaxime and clindamycin use in a 6 year-old boy: a case report. <i>Pan Afr Med J</i>. 2017;28:218. doi:10.11604/pamj.2017.28.218.10828<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/29629004/pubmed" id="29629004" target="_blank">29629004</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3184334">
<a name="3184334"></a>Klempner MS, Styrt B. Prevention of recurrent staphylococcal skin infections with low-dose oral clindamycin therapy. <i>JAMA</i>. 1988;260(18):2682-2685.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/3184334/pubmed" id="3184334" target="_blank">3184334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Klompas.1">
<a name="Klompas.1"></a>Klompas M. Aspiration pneumonia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 27, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20824827">
<a name="20824827"></a>Kozyrskyj A, Klassen TP, Moffatt M, Harvey K. Short-course antibiotics for acute otitis media. <i>Cochrane Database Syst Rev</i>. 2010;2010(9):CD001095. doi:10.1002/14651858.CD001095.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/20824827/pubmed" id="20824827" target="_blank">20824827</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33501959">
<a name="33501959"></a>Krause PJ, Auwaerter PG, Bannuru RR, et al. Clinical practice guidelines by the Infectious Diseases Society of America (IDSA): 2020 guideline on diagnosis and management of babesiosis. <i>Clin Infect Dis</i>. 2021;72(2):185-189. doi:10.1093/cid/ciab050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/33501959/pubmed" id="33501959" target="_blank">33501959</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18181735">
<a name="18181735"></a>Krause PJ, Gewurz BE, Hill D, et al. Persistent and relapsing babesiosis in immunocompromised patients. <i>Clin Infect Dis.</i> 2008;46(3):370-376. doi:10.1086/525852<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/18181735/pubmed" id="18181735" target="_blank">18181735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3501426">
<a name="3501426"></a>Kuenzi B, Segessenmann C, Gerber AU. Postantibiotic effect of roxithromycin, erythromycin, and clindamycin against selected gram-positive bacteria and Haemophilus influenzae. <i>J Antimicrob Chemother</i>. 1987;20(suppl B):39-46. doi:10.1093/jac/20.suppl_b.39<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/3501426/pubmed" id="3501426" target="_blank">3501426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lalani.1">
<a name="Lalani.1"></a>Lalani T. Overview of osteomyelitis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 30, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18411321">
<a name="18411321"></a>LaPlante KL, Leonard SN, Andes DR, Craig WA, Rybak MJ. Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vitro pharmacodynamic models. <i>Antimicrob Agents Chemother.</i> 2008;52(6):2156-2162. doi:10.1128/AAC.01046-07<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/18411321/pubmed" id="18411321" target="_blank">18411321</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19393958">
<a name="19393958"></a>Lappin E, Ferguson AJ. Gram-positive toxic shock syndromes. <i>Lancet Infect Dis</i>. 2009;9(5):281-290.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/19393958/pubmed" id="19393958" target="_blank">19393958</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19909885">
<a name="19909885"></a>Levison ME, Levison JH. Pharmacokinetics and pharmacodynamics of antibacterial agents. <i>Infect Dis Clin North Am</i>. 2009;23(4):791-815, vii. doi:10.1016/j.idc.2009.06.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/19909885/pubmed" id="19909885" target="_blank">19909885</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10428927">
<a name="10428927"></a>Lewis RE, Klepser ME, Ernst EJ, Lund BC, Biedenbach DJ, Jones RN. Evaluation of low-dose, extended-interval clindamycin regimens against Staphylococcus aureus and Streptococcus pneumoniae using a dynamic in vitro model of infection. <i>Antimicrob Agents Chemother.</i> 1999;43(8):2005-2009. doi:10.1128/AAC.43.8.2005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/10428927/pubmed" id="10428927" target="_blank">10428927</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23439909">
<a name="23439909"></a>Lieberthal AS, Carroll AE, Chonmaitree T, et al. The diagnosis and management of acute otitis media. <i>Pediatrics</i>. 2013;131(3):e964-e999.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/23439909/pubmed" id="23439909" target="_blank">23439909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22619242">
<a name="22619242"></a>Lipsky BA, Berendt AR, Cornia PB, et al; Infectious Diseases Society of America. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. <i>Clin Infect Dis.</i> 2012;54(12):e132-e173.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/22619242/pubmed" id="22619242" target="_blank">22619242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2183732">
<a name="2183732"></a>Lipsky BA, Pecoraro RE, Larson SA, Hanley ME, Ahroni JH. Outpatient management of uncomplicated lower-extremity infections in diabetic patients. <i>Arch Intern Med</i>. 1990;150(4):790-797.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/2183732/pubmed" id="2183732" target="_blank">2183732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30020891">
<a name="30020891"></a>Litao G, Jingjing S, Yu L, Lei Z, Xiaona H, Zhijing Z. Risk factors for antibiotic-associated diarrhea in critically ill patients. <i>Med Sci Monit</i>. 2018;24:5000-5007. doi:10.12659/MSM.911308<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/30020891/pubmed" id="30020891" target="_blank">30020891</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21217178">
<a name="21217178"></a>Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant <i>Staphylococcus aureus</i> infections in adults and children: executive summary. <i>Clin Infect Dis.</i> 2011;52(3):285-292.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/21217178/pubmed" id="21217178" target="_blank">21217178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20173050">
<a name="20173050"></a>Lobo LJ, Reed KD, Wunderink RG. Expanded clinical presentation of community-acquired methicillin-resistant Staphylococcus aureus pneumonia. <i>Chest</i>. 2010;138(1):130-136. doi:10.1378/chest.09-1562<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/20173050/pubmed" id="20173050" target="_blank">20173050</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31668170">
<a name="31668170"></a>Lockhart PB, Tampi MP, Abt E, et al. Evidence-based clinical practice guideline on antibiotic use for the urgent management of pulpal- and periapical-related dental pain and intraoral swelling: A report from the American Dental Association. <i>J Am Dent Assoc</i>. 2019;150(11):906-921.e12. doi:10.1016/j.adaj.2019.08.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/31668170/pubmed" id="31668170" target="_blank">31668170</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-850084">
<a name="850084"></a>Lusk RH, Fekety FR Jr, Silva J Jr, et al. Gastrointestinal side effects of clindamycin and ampicillin therapy. <i>J Infect Dis</i>. 1977;135 Suppl:S111-S119. doi:10.1093/infdis/135.supplement.s111<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/850084/pubmed" id="850084" target="_blank">850084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31118710">
<a name="31118710"></a>Ma H, Zhang L, Zhang Y, Liu Y, He Y, Guo L. Combined administration of antibiotics increases the incidence of antibiotic-associated diarrhea in critically ill patients. <i>Infect Drug Resist</i>. 2019;12:1047-1054. doi:10.2147/IDR.S194715<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/31118710/pubmed" id="31118710" target="_blank">31118710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25922861">
<a name="25922861"></a>Mackeen AD, Packard RE, Ota E, Speer L. Antibiotic regimens for postpartum endometritis. <i>Cochrane Database Syst Rev</i>. 2015;(2):CD001067. doi: 10.1002/14651858.CD001067.pub3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/25922861/pubmed" id="25922861" target="_blank">25922861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1211913">
<a name="1211913"></a>Malacoff RF, Finkelstein FO, Andriole VT. Effect of peritoneal dialysis on serum levels of tobramycin and clindamycin. <i>Antimicrob Agents Chemother</i>. 1975;8(5):574-580.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/1211913/pubmed" id="1211913" target="_blank">1211913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7454470">
<a name="7454470"></a>Mann CF. Clindamycin and breast-feeding. <i>Pediatrics.</i> 1980;66(6):1030-1031.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/7454470/pubmed" id="7454470" target="_blank">7454470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31876601">
<a name="31876601"></a>Marchisio P, Galli L, Bortone B, et al. Updated guidelines for the management of acute otitis media in children by the Italian Society of Pediatrics: treatment. <i>Pediatr Infect Dis J</i>. 2019;38(12S suppl):S10-S21. doi:10.1097/INF.0000000000002452<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/31876601/pubmed" id="31876601" target="_blank">31876601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29462280">
<a name="29462280"></a>McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for <i>Clostridium difficile</i> infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). <i>Clin Infect Dis</i>. 2018;66(7):e1-e48. doi:10.1093/cid/cix1085<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/29462280/pubmed" id="29462280" target="_blank">29462280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27003987">
<a name="27003987"></a>McFarland LV, Ozen M, Dinleyici EC, Goh S. Comparison of pediatric and adult antibiotic-associated diarrhea and <i>Clostridium difficile</i> infections. <i>World J Gastroenterol</i>. 2016;22(11):3078-3104. doi:10.3748/wjg.v22.i11.3078<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/27003987/pubmed" id="27003987" target="_blank">27003987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24457117">
<a name="24457117"></a>Meaney-Delman D, Zotti ME, Creanga AA, et al; Workgroup on Anthrax in Pregnant and Postpartum Women. Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women. <i>Emerg Infect Dis</i>. 2014;20(2). doi: 10.3201/eid2002.130611.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/24457117/pubmed" id="24457117" target="_blank">24457117</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31573350">
<a name="31573350"></a>Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. <i>Am J Resp Crit Care Med</i>. 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581ST.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/31573350/pubmed" id="31573350" target="_blank">31573350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23165860">
<a name="23165860"></a>Miller Quidley A, Bookstaver PB, Gainey AB, Gainey MD. Fatal clindamycin-induced drug rash with eosinophilia and systemic symptoms (DRESS) syndrome. <i>Pharmacotherapy</i>. 2012;32(12):e387-e392. doi:10.1002/phar.1142<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/23165860/pubmed" id="23165860" target="_blank">23165860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35576513">
<a name="35576513"></a>Mitchell KB, Johnson HM, Rodríguez JM, et al; Academy of Breastfeeding Medicine. Academy of Breastfeeding Medicine clinical protocol #36: the mastitis spectrum, revised 2022. <i>Breastfeed Med</i>. 2022;17(5):360-376. doi:10.1089/bfm.2022.29207.kbm<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/35576513/pubmed" id="35576513" target="_blank">35576513</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24387005">
<a name="24387005"></a>Morales MP, Carvallo AP, Espinosa KA, Murillo EE. A young man with myelosuppression caused by clindamycin: a case report. <i>J Med Case Rep</i>. 2014;8:7. doi:10.1186/1752-1947-8-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/24387005/pubmed" id="24387005" target="_blank">24387005</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20176904">
<a name="20176904"></a>Muller AE, Mouton JW, Oostvogel PM, et al. Pharmacokinetics of clindamycin in pregnant women in the peripartum period. <i>Antimicrob Agents Chemother.</i> 2010;54(5):2175-2181. doi:10.1128/AAC.01017-09<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/20176904/pubmed" id="20176904" target="_blank">20176904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29408016">
<a name="29408016"></a>Nasiri MJ, Goudarzi M, Hajikhani B, Ghazi M, Goudarzi H, Pouriran R. <i>Clostridioides (Clostridium) difficile</i> infection in hospitalized patients with antibiotic-associated diarrhea: a systematic review and meta-analysis. <i>Anaerobe</i>. 2018;50:32-37. doi:10.1016/j.anaerobe.2018.01.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/29408016/pubmed" id="29408016" target="_blank">29408016</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE). Otitis media (acute): antimicrobial prescribing. London, UK: National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/ng91. Published March 2018. Accessed November 3, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28315732">
<a name="28315732"></a>Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>J Am Coll Cardiol</i>. 2017;70(2):252-289. doi:10.1016/j.jacc.2017.03.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/28315732/pubmed" id="28315732" target="_blank">28315732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29858291">
<a name="29858291"></a>Ondusko DS, Nolt D. <i>Staphylococcus aureus</i>. <i>Pediatr Rev</i>. 2018;39(6):287-298. doi:10.1542/pir.2017-0224<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/29858291/pubmed" id="29858291" target="_blank">29858291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23223583">
<a name="23223583"></a>Osmon DR, Berbari EF, Berendt AR, et al; Infectious Diseases Society of America. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2013;56(1):e1-e25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/23223583/pubmed" id="23223583" target="_blank">23223583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Osmon.2019">
<a name="Osmon.2019"></a>Osmon DR, Tande AJ. Nonvertebral osteomyelitis in adults: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 27, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7748763">
<a name="7748763"></a>Paquet P, Schaaf-Lafontaine N, Piérard GE. Toxic epidermal necrolysis following clindamycin treatment. <i>Br J Dermatol</i>. 1995;132(4):665-666. doi:10.1111/j.1365-2133.1995.tb08730.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/7748763/pubmed" id="7748763" target="_blank">7748763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32577121">
<a name="32577121"></a>Paradis N, Marois L, Paradis L, Graham F, Bégin P, Des Roches A. Anaphylaxis to clindamycin following cutaneous exposure. <i>Allergy Asthma Clin Immunol</i>. 2020;16:51. doi:10.1186/s13223-020-00452-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/32577121/pubmed" id="32577121" target="_blank">32577121</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Patel.2018">
<a name="Patel.2018"></a>Patel ZM, Hwang PH. Uncomplicated acute sinusitis and rhinosinusitis in adults: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 27, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17385141">
<a name="17385141"></a>Peled N, Pitlik S, Samra Z, Kazakov A, Bloch Y, Bishara J. Predicting <i>Clostridium difficile</i> toxin in hospitalized patients with antibiotic-associated diarrhea. <i>Infect Control Hosp Epidemiol</i>. 2007;28(4):377-381. doi:10.1086/513723<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/17385141/pubmed" id="17385141" target="_blank">17385141</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33683325">
<a name="33683325"></a>Pernica JM, Harman S, Kam AJ, et al. Short-course antimicrobial therapy for pediatric community-acquired pneumonia: The SAFER randomized clinical trial. <i>JAMA Pediatr</i>. 2021;175(5):475-482. doi:10.1001/jamapediatrics.2020.6735<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/33683325/pubmed" id="33683325" target="_blank">33683325</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1245094">
<a name="1245094"></a>Philipson A, Sabath LD, Charles D. Erythromycin and clindamycin absorption and elimination in pregnant women. <i>Clin Pharmacol Ther.</i> 1976;19(1):68-77.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/1245094/pubmed" id="1245094" target="_blank">1245094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4700555">
<a name="4700555"></a>Philipson A, Sabath LD, Charles D. Transplacental passage of erythromycin and clindamycin. <i>N Engl J Med</i>, 1973;288(23):1219-1221. doi: 10.1056/NEJM197306072882307.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/4700555/pubmed" id="4700555" target="_blank">4700555</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8416289">
<a name="8416289"></a>Pisciotta AV. Agranulocytosis during antibiotic therapy: drug sensitivity or sepsis? <i>Am J Hematol</i>. 1993;42(1):132-137. doi:10.1002/ajh.2830420126<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/8416289/pubmed" id="8416289" target="_blank">8416289</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27602668">
<a name="27602668"></a>Rosenfeld RM. Clinical Practice. Acute sinusitis in adults.<i> N Engl J Med.</i> 2016;375(10):962-970. doi: 10.1056/NEJMcp1601749.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/27602668/pubmed" id="27602668" target="_blank">27602668</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25832968">
<a name="25832968"></a>Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. <i>Otolaryngol Head Neck Surg</i>. 2015;152(2)(suppl):S1-S39. doi: 10.1177/0194599815572097.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/25832968/pubmed" id="25832968" target="_blank">25832968</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8490912">
<a name="8490912"></a>Rubenstein EB, Rolston K, Benjamin RS, et al. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. <i>Cancer</i>. 1993;71(11):3640-3646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/8490912/pubmed" id="8490912" target="_blank">8490912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28708801">
<a name="28708801"></a>Saavedra-Lozano J, Falup-Pecurariu O, Faust SN, et al. Bone and joint infections. <i>Pediatr Infect Dis J</i>. 2017;36(8):788-799. doi:10.1097/INF.0000000000001635<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/28708801/pubmed" id="28708801" target="_blank">28708801</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8610948">
<a name="8610948"></a>Safrin S, Finkelstein DM, Feinberg J, et al. Comparison of three regimens for treatment of mild-to-moderate <i>Pneumocystis carinii</i> pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study Group. <i>Ann Intern Med.</i> 1996;124(9):792-802.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/8610948/pubmed" id="8610948" target="_blank">8610948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32525203">
<a name="32525203"></a>Same RG, Amoah J, Hsu AJ, et al. The association of antibiotic duration with successful treatment of community-acquired pneumonia in children. <i>J Pediatric Infect Dis Soc</i>. 2021;10(3):267-273. doi:10.1093/jpids/piaa055<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/32525203/pubmed" id="32525203" target="_blank">32525203</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27115378">
<a name="27115378"></a>Sanchez E, Vannier E, Wormser GP, Hu LT. Diagnosis, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: a review. <i>JAMA</i>. 2016;315(16):1767-1777. doi:10.1001/jama.2016.2884<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/27115378/pubmed" id="27115378" target="_blank">27115378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23465021">
<a name="23465021"></a>Schwartz BS, Mawhorter SD; AST Infectious Diseases Community of Practice. Parasitic infections in solid organ transplantation. <i>Am J Transplant</i>. 2013;13(suppl 4):280-303. doi: 10.1111/ajt.12120.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/23465021/pubmed" id="23465021" target="_blank">23465021</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21764170">
<a name="21764170"></a>Sendi P, Christensson B, Uçkay I, et al; GBS PJI study group. Group B streptococcus in prosthetic hip and knee joint-associated infections. <i>J Hosp Infect</i>. 2011;79(1):64-69. doi: 10.1016/j.jhin.2011.04.022.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/21764170/pubmed" id="21764170" target="_blank">21764170</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29053792">
<a name="29053792"></a>Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea. <i>Clin Infect Dis</i>. 2017;65(12):e45-e80. doi:10.1093/cid/cix669<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/29053792/pubmed" id="29053792" target="_blank">29053792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22965026">
<a name="22965026"></a>Shulman ST, Bisno AL, Clegg HW, et al; Infectious Diseases Society of America. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2012;55(10):e86-e102.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/22965026/pubmed" id="22965026" target="_blank">22965026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24324224">
<a name="24324224"></a>Slimings C, Riley TV. Antibiotics and hospital-acquired <i>Clostridium difficile</i> infection: update of systematic review and meta-analysis. <i>J Antimicrob Chemother</i>. 2014;69(4):881-891. doi:10.1093/jac/dkt477<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/24324224/pubmed" id="24324224" target="_blank">24324224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28137820">
<a name="28137820"></a>Smith MJ, Gonzalez D, Goldman JL, et al. Pharmacokinetics of clindamycin in obese and nonobese children. <i>Antimicrob Agents Chemother</i>. 2017;61(4):e02014-e02016.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/28137820/pubmed" id="28137820" target="_blank">28137820</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25569493">
<a name="25569493"></a>Sollecito TP, Abt E, Lockhart PB, et al. The use of prophylactic antibiotics prior to dental procedures in patients with prosthetic joints: Evidence-based clinical practice guideline for dental practitioners--a report of the American Dental Association Council on Scientific Affairs. <i>J Am Dent Assoc.</i> 2015;146(1):11-16. doi: 10.1016/j.adaj.2014.11.012.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/25569493/pubmed" id="25569493" target="_blank">25569493</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20034345">
<a name="20034345"></a>Solomkin JS, Mazuski JE, Bradley JS, et al, "Diagnosis and Management of Complicated Intra-abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America," <i>Clin Infect Dis</i>, 2010, 50(2):133-64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/20034345/pubmed" id="20034345" target="_blank">20034345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Spelman.2018">
<a name="Spelman.2018"></a>Spelman D, Baddour LM. Acute cellulitis and erysipelas in adults: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 24, 2023a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Spelman.2">
<a name="Spelman.2"></a>Spelman D, Baddour LM. Skin abscesses in adults: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 24, 2023b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7082533">
<a name="7082533"></a>Stéen B, Rane A. Clindamycin passage into human milk. <i>Br J Clin Pharmacol.</i> 1982;13(5):661-664.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/7082533 /pubmed" id="7082533 " target="_blank">7082533 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stevens.2018a">
<a name="Stevens.2018a"></a>Stevens DL, Baddour LM. Necrotizing soft tissue infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 1, 2023a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stevens.2019b">
<a name="Stevens.2019b"></a>Stevens DL. Invasive group A streptococcal infection and toxic shock syndrome: treatment and prevention. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 20, 2023b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24947530">
<a name="24947530"></a>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(2):147-159. doi:10.1093/cid/ciu296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/24947530/pubmed" id="24947530" target="_blank">24947530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21653301">
<a name="21653301"></a>Stevens V, Dumyati G, Fine LS, Fisher SG, van Wijngaarden E. Cumulative antibiotic exposures over time and the risk of <i>Clostridium difficile</i> infection. <i>Clin Infect Dis</i>. 2011;53(1):42-48. doi:10.1093/cid/cir301<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/21653301/pubmed" id="21653301" target="_blank">21653301</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30799434">
<a name="30799434"></a>Subedi P, Chowdhury A, Tanovic K, Dumic I. Clindamycin: An unusual cause of acute kidney injury. <i>Am J Case Rep</i>. 2019;20:248-251. Published 2019 Feb 25. doi:10.12659/AJCR.913779<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/30799434/pubmed" id="30799434" target="_blank">30799434</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29461916">
<a name="29461916"></a>Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America clinical practice guideline update. <i>J Clin Oncol</i>. 2018;36(14):1443-1453. doi: 10.1200/JCO.2017.77.6211.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/29461916/pubmed" id="29461916" target="_blank">29461916</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Thomas.2018">
<a name="Thomas.2018"></a>Thomas CF, Limper AH. Treatment and prevention of pneumocystis pneumonia in HIV-uninfected patients. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 6, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20843501">
<a name="20843501"></a>Tian D, Mohan RJ, Stallings G. Drug rash with eosinophilia and systemic symptoms syndrome associated with clindamycin. <i>Am J Med</i>. 2010;123(11):e7-e8. doi:10.1016/j.amjmed.2010.04.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/20843501/pubmed" id="20843501" target="_blank">20843501</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16163635">
<a name="16163635"></a>Trotman RL, Williamson JC, Shoemaker DM, et al, “Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,” <i> Clin Infect Dis</i>, 2005, 41(8):1159-66.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/16163635/pubmed" id="16163635" target="_blank">16163635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26685211">
<a name="26685211"></a>Tseng J, Maurer T, Mutizwa MM. HIV-associated toxic epidermal necrolysis at San Francisco General Hospital. <i>J Int Assoc Provid AIDS Care</i>. 2017;16(1):37-41. doi:10.1177/2325957415614651<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/26685211/pubmed" id="26685211" target="_blank">26685211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12827001">
<a name="12827001"></a>Turck D, Bernet JP, Marx J, et al. Incidence and risk factors of oral antibiotic-associated diarrhea in an outpatient pediatric population. <i>J Pediatr Gastroenterol Nutr</i>. 2003;37(1):22-26. doi:10.1097/00005176-200307000-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/12827001/pubmed" id="12827001" target="_blank">12827001</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services (HHS) Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. March 1, 2016. <a href="http://aidsinfo.nih.gov" target="_blank">http://aidsinfo.nih.gov</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2">
<a name="HHS.2"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-oi-prevention-and-treatment-guidelines/0%20" target="_blank">https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-oi-prevention-and-treatment-guidelines/0</a>. Accessed April 30, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.3">
<a name="HHS.3"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. <a href="https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines</a>. Updated August 18, 2021. Accessed August 20, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.4">
<a name="HHS.4"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. <a href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection/whats-new</a>. Updated March 19, 2021. Accessed August 20, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22716978">
<a name="22716978"></a>Vannier E, Krause PJ. Human babesiosis. <i>N Engl J Med</i>. 2012;366(25):2397-2407. doi: 10.1056/NEJMra1202018.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/22716978/pubmed" id="22716978" target="_blank">22716978</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27216385">
<a name="27216385"></a>Vardakas KZ, Trigkidis KK, Boukouvala E, Falagas ME. <i>Clostridium difficile</i> infection following systemic antibiotic administration in randomised controlled trials: a systematic review and meta-analysis. <i>Int J Antimicrob Agents</i>. 2016;48(1):1-10. doi:10.1016/j.ijantimicag.2016.03.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/27216385/pubmed" id="27216385" target="_blank">27216385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VON.1">
<a name="VON.1"></a>Vermont Oxford Network (VON). Neonatal drug concentrations. Updated November 2022. Accessed August 10, 2023. https://public.vtoxford.org/neonatal-drug-concentrations
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31668055">
<a name="31668055"></a>Vílchez-Sánchez F, Domínguez-Ortega J, González Muñoz M, et al. Two case reports of delayed-allergic reactions to clindamycin confirmed with a positive lymphocyte transformation test. <i>Eur Ann Allergy Clin Immunol</i>. 2020;52(2):91-93. doi:10.23822/EurAnnACI.1764-1489.117<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/31668055/pubmed" id="31668055" target="_blank">31668055</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22851742">
<a name="22851742"></a>Warady BA, Bakkaloglu S, Newland J, et al "Consensus Guidelines for the Prevention and Treatment of Catheter-Related Infections and Peritonitis in Pediatric Patients Receiving Peritoneal Dialysis: 2012 Update," <i>Perit Dial Int</i>, 2012, 32(Suppl 2):S32-86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/22851742/pubmed" id="22851742" target="_blank">22851742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29272341">
<a name="29272341"></a>Watson T, Hickok J, Fraker S, Korwek K, Poland RE, Septimus E. Evaluating the risk factors for hospital-onset <i>Clostridium difficile</i> infections in a large healthcare system. <i>Clin Infect Dis</i>. 2018;66(12):1957-1959. doi:10.1093/cid/cix1112<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/29272341/pubmed" id="29272341" target="_blank">29272341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-943947">
<a name="943947"></a>Weinstein AJ, Gibbs RS, Gallagher M. Placental transfer of clindamycin and gentamicin in term pregnancy. <i>Am J Obstet Gynecol.</i> 1976;124(7):688-691.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/943947/pubmed" id="943947" target="_blank">943947</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Weintrob.2018">
<a name="Weintrob.2018"></a>Weintrob AC, Sexton DJ. Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 27, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wiesenfeld.1">
<a name="Wiesenfeld.1"></a>Wiesenfeld HC. Pelvic inflammatory disease: treatment in adults and adolescents. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 11, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wilson.2">
<a name="Wilson.2"></a>Wilson KH. Prevention of anthrax. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 21, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wilson.1">
<a name="Wilson.1"></a>Wilson W, Taubert KA, Gewitz M, et al, "Prevention of Infective Endocarditis. Guidelines From the American Heart Association," <i>Circulation</i>, 2007, 115:1-20.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17446442">
<a name="17446442"></a>Wilson W, Taubert KA, Gewitz M, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee; American Heart Association Council on Cardiovascular Disease in the Young; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Cardiovascular Surgery and Anesthesia; Quality of Care and Outcomes Research Interdisciplinary Working Group. Prevention of infective endocarditis. Guidelines from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group [published correction appears in <i>Circulation. </i>2007;116(15):e376-e377]. <i>Circulation.</i> 2007;116(15):1736-1754.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/17446442/pubmed" id="17446442" target="_blank">17446442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33853363">
<a name="33853363"></a>Wilson WR, Gewitz M, Lockhart PB, et al; American Heart Association Young Hearts Rheumatic Fever, Endocarditis and Kawasaki Disease Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Cardiovascular and Stroke Nursing; and the Council on Quality of Care and Outcomes Research. Prevention of Viridans group Streptococcal infective endocarditis: a scientific statement from the American Heart Association. <i>Circulation</i>. 2021;143(20):e963-e978. doi:10.1161/CIR.0000000000000969<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/33853363/pubmed" id="33853363" target="_blank">33853363</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23809722">
<a name="23809722"></a>Wong CJ, Stevens DL. Serious group A streptococcal infections. <i>Med Clin North Am</i>. 2013;97(4):721-736.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/23809722/pubmed" id="23809722" target="_blank">23809722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34350458">
<a name="34350458"></a>Woods CR, Bradley JS, Chatterjee A, et al. Clinical practice guideline by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America: 2021 guideline on diagnosis and management of acute hematogenous osteomyelitis in pediatrics. <i>J Pediatric Infect Dis Soc</i>. Published online August 5, 2021. doi:10.1093/jpids/piab027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/34350458/pubmed" id="34350458" target="_blank">34350458</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34292926">
<a name="34292926"></a>Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. <i>MMWR Recomm Rep</i>. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/34292926/pubmed" id="34292926" target="_blank">34292926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO), <i>Anthrax in Humans and Animals</i>, 4th ed, 2008. http://whqlibdoc.who.int/publications/2008/9789241547536_eng.pdf
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2">
<a name="WHO.2"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the Eleventh WHO Model List of Essential Drugs. 2002. https://apps.who.int/iris/handle/10665/62435
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.3">
<a name="WHO.3"></a>World Health Organization (WHO). WHO guidelines for malaria (2023). https://www.who.int/publications/i/item/guidelines-for-malaria. Published March 14, 2023. Accessed July 20, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.4">
<a name="WHO.4"></a>World Health Organization. (‎2000)‎. Mastitis: causes and management. World Health Organization. https://apps.who.int/iris/handle/10665/66230
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8726009">
<a name="8726009"></a>Xue IB, Davey PG, Phillips G. Variation in postantibiotic effect of clindamycin against clinical isolates of Staphylococcus aureus and implications for dosing of patients with osteomyelitis. <i>Antimicrob Agents Chemother</i>. 1996;40(6):1403-1407. doi:10.1128/AAC.40.6.1403<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/8726009/pubmed" id="8726009" target="_blank">8726009</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27527109">
<a name="27527109"></a>Yang Y, Chen S, Yang F, et al. HLA-B*51:01 is strongly associated with clindamycin-related cutaneous adverse drug reactions. <i>Pharmacogenomics J</i>. 2017;17(6):501-505. doi:10.1038/tpj.2016.61<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/27527109/pubmed" id="27527109" target="_blank">27527109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32518780">
<a name="32518780"></a>Zhou H, Xu Q, Liu Y, Guo LT. Risk factors, incidence, and morbidity associated with antibiotic-associated diarrhea in intensive care unit patients receiving antibiotic monotherapy. <i>World J Clin Cases</i>. 2020;8(10):1908-1915. doi:10.12998/wjcc.v8.i10.1908<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/32518780/pubmed" id="32518780" target="_blank">32518780</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25640693">
<a name="25640693"></a>Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. <i>J Eur Acad Dermatol Venereol</i>. 2015;29(4):619-644. doi: 10.1111/jdv.12966.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clindamycin-systemic-drug-information/abstract-text/25640693/pubmed" id="25640693" target="_blank">25640693</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9064 Version 685.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
